No retraction, correction or concern found when last checked on Oct 19, 2026.

Physiology and Pathophysiology of Steroid Biosynthesis, Transport and Metabolism in the Human Placenta

Waranya Chatuphonprasert, Kanokwan Jarukamjorn, Isabella Ellinger

Frontiers in Pharmacology · 2018 · Review

doi:10.3389/fphar.2018.01027

Abstract

The steroid hormones progestagens, estrogens, androgens, and glucocorticoids as well as their precursor cholesterol are required for successful establishment and maintenance of pregnancy and proper development of the fetus. The human placenta forms at the interface of maternal and fetal circulation. It participates in biosynthesis and metabolism of steroids as well as their regulated exchange between maternal and fetal compartment. This review outlines the mechanisms of human placental handling of steroid compounds. Cholesterol is transported from mother to offspring involving lipoprotein receptors such as low-density lipoprotein receptor (LDLR) and scavenger receptor class B type I (SRB1) as well as ATP-binding cassette (ABC)-transporters, ABCA1 and ABCG1. Additionally, cholesterol is also a precursor for placental progesterone and estrogen synthesis. Hormone synthesis is predominantly performed by members of the cytochrome P-450 (CYP) enzyme family including CYP11A1 or CYP19A1 and hydroxysteroid dehydrogenases (HSDs) such as 3β-HSD and 17β-HSD. Placental estrogen synthesis requires delivery of sulfate-conjugated precursor molecules from fetal and maternal serum. Placental uptake of these precursors is mediated by members of the solute carrier (SLC) family including sodium-dependent organic anion transporter (SOAT), organic anion transporter 4 (OAT4), and organic anion transporting polypeptide 2B1 (OATP2B1). Maternal-fetal glucocorticoid transport has to be tightly regulated in order to ensure healthy fetal growth and development. For that purpose, the placenta expresses the enzymes 11β-HSD 1 and 2 as well as the transporter ABCB1. This article also summarizes the impact of diverse compounds and diseases on the expression level and activity of the involved transporters, receptors, and metabolizing enzymes and concludes that the regulatory mechanisms changing the physiological to a pathophysiological state are barely explored. The structure and the cellular composition of the human placental barrier are introduced. While steroid production, metabolism and transport in the placental syncytiotrophoblast have been explored for decades, few information is available for the role of placental-fetal endothelial cells in these processes. With regard to placental structure and function, significant differences exist between species. To further decipher physiologic pathways and their pathologic alterations in placental steroid handling, proper model systems are mandatory.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 20, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1The placenta is a multifunctional organ enabling optimal fetal growth. Structure and function can adapt to diverse external stressors. In case of failure of adaptation or inadequate placental development, fetal survival or fetal growth and development are endangered and developmental programming of adult diseases may occur. Moreover, the placenta contributes to maternal diseases such as preeclampsia, which predispose the mother to lifelong illness.

2Essential placental functions are biosynthesis, metabolism, and transport of cholesterol, sex hormones and glucocorticoids. This article summarizes placental handling of these steroids under physiologic conditions and gives an overview on changes observed due to maternal diseases and exogenous influences. Whenever possible, data obtained in human placenta or human in vitro systems are referenced. We also draw attention to open research questions.

The Human Placental Barrier And Placental Model Systems

3The hemochorial human placenta results from a deep invasion of embryonic cells during implantation. The mature human placenta is a disk delimited by chorionic and basal plate (Figure 1A), which enclose the intervillous space filled with maternal blood. The basal plate contacts the uterine wall. From the chorionic plate, both umbilical cord and the branched chorionic villi originate. The cells of the chorionic villi form the “placental barrier,” which prevents direct contact of maternal and fetal blood. Biosynthesis, metabolism, and transport of steroids occur in the chorionic villi.

4Chorionic villi are composed of several cell types. The STB, an epithelial multinucleated syncytium, covers the surface of the chorionic villi. The microvillous apical membrane of the STB contacts maternal blood, while the basal plasma membrane of the STB is directed toward the stromal core of the villi. Apical and basal plasma membranes of the STB are often regarded as the most important membrane barriers in the materno-fetal transport processes. Nutrients, hormones, or fetal waste products traverse the STB by different transport mechanisms. Mononuclear CTB are located below the STB. They proliferate and fuse into the STB, thus supporting growth and regeneration of this layer. Early in pregnancy, CTBs form a continuous layer beneath the STB (Figure 1B). With progressing pregnancy, CTBs transform from a cuboidal into a flat phenotype. The CTB layer becomes incomplete, but maintains a functional network due to multiple interconnecting cell processes (; Figure 1C).

5The stromal core of the chorionic villi contains fetal blood vessels delineated by pFECs, macrophages and additional stromal cells, which are all embedded in a non-cellular matrix. pFECs are non-fenestrated endothelial cells. Early placental pFECs are probably more permeable than term pFECs. Recent years of research have demonstrated the importance of pFEC function for the fetal development. Heterogeneity of pFECs in the macro-circulation (umbilical cord) and microcirculation (chorionic villi) was shown in situ and in vitro. Moreover, venous and arterial pFECs, which differ in their phenotypic, genotypic, and functional characteristics, have been described. The term placenta has a high degree of vascularity. The capillaries closely approximate the villous covering, thereby forming “vasculosyncytial membranes” that are important for materno-fetal exchange processes. Thus, the term maternal–fetal interface or placental barrier consists of a thin cytoplasmic layer of STB apposed to a capillary (Figure 1C). Between the STB and pFEC the extracellular matrix is reduced to their fused basal laminae. STB and pFEC actively regulate uptake, metabolism, and transfer/exchange of molecules, while the non-cellular structures probably act as filters and provide transient storage capability.

6The placenta undergoes significant anatomical changes in the course of pregnancy, which are relevant to maintain appropriate placental function as pregnancy progresses. Hormones in the fetal and maternal circulations have an important role in determining the placental phenotype. As a developing organ that constantly adapts to the maternal environment, not only the structure, but also the transcriptome changes over time. In line with this, expression of various placental genes involved in biosynthesis, transfer or metabolism of steroids changes during pregnancy (see below).

7The structure of the placenta is species-specific. Thus, no perfect animal model for the human placenta exists and special care must be taken with extrapolation of data from one species to another. Higher order primates including old world monkeys such as baboons are most closely aligned to humans with respect to structure as well as regulation of steroidogenesis. Species-specific placental anatomy, endocrine function or advantages and limitations of relevant animal models to study the function of the human placenta in health and disease are detailed in various review articles.

8Placental functions can also be studied in human ex vivo models such as the isolated perfused placenta and placental villous tissue explants. Commonly used in vitro models are (1) isolated and in vitro cultured placental primary cells including trophoblasts as well as primary arterial and venous pFECs; (2) diverse, mainly trophoblastic cell lines derived by either transfection or spontaneous mutation including the choriocarcinoma cell lines BeWo, JEG-3, and Jar; and (3) isolated membrane vesicles. Choriocarcinoma cell lines are the most extensively used cell models. Their disadvantage is their origin from tumors. GeneChip analysis has revealed considerable differences between the gene expression patterns of choriocarcinoma cell lines and primary placental cells. Thus, results obtained in cell lines should always be interpreted carefully and best be confirmed in other in vitro or ex vivo models. Over the last years co-cultures of trophoblast cells with endothelial cells have been established in order to mimic the entire placental barrier. In the future, they may become attractive models to study transplacental transport processes and functional interdependence of cells.

Cholesterol

9Cholesterol (Figure 2B) is an essential component of cell membranes influencing their integrity, fluidity, and permeability, equally important for the growing placenta and fetus. The human placenta needs more than 1 g of cholesterol for tissue growth and the term human placenta manufactures approximately 400 mg of sex steroids from the precursor cholesterol per day. Cholesterol is essential for myelination and as an activator and propagator of the sonic hedgehog-signaling pathway. Thus, cholesterol is indispensable for patterning and development of the fetal nervous system.

10Oxysterols are structurally closely related to cholesterol (Figures 2C–E) and have regulatory functions in cholesterol metabolism. They are not only generated by enzymes, but also formed by autoxidation and thus accumulate under increased oxidative stress.

11According to the WHO, in 2008 the global prevalence of raised total cholesterol among female adults (≥5.0 mmol/l) was 40%; thus, hypercholesterolemia became a major health care problem. Various studies have indicated that maternal hypercholesterolemia, but also maternal hypocholesterolemia negatively impact pregnancy outcome. Among the observed consequences are preterm delivery, low birth weight, IUGR, and changes in the fetal aorta that determine the long-term susceptibility of children to fatty-streak formation and subsequent atherosclerosis. Furthermore, altered mRNA expression levels of placental lipoprotein receptors involved in cholesterol uptake were observed.

12As described below, also diseases of pregnancy and various endogenous and exogenous compounds can affect the placental proteins involved in cholesterol biosynthesis, metabolism, and transport. The long-term consequences for the fetus are hardly known. Thus, we need to further explore the regulation of cholesterol-associated pathways in placentas in healthy and diseased pregnancies in order to understand the correlation between observed changes in utero and diseases developing during later lives.

Cholesterol Biosynthesis and Homeostasis

13Cellular cholesterol homeostasis includes tightly regulated processes, which are summarized in Figure 3. Intracellular cholesterol synthesis starts from acetyl-coenzyme A (acetyl-CoA). Lanosterol, the first sterol, feeds into two pathways, the Bloch and the Kandutsch–Russell pathway that both result in cholesterol production. The rate-limiting and committed step is the conversion of HMG-CoA to mevalonate mediated by HMGR. HMGR is regulated by endogenous molecules including transcription factor SREBP2 as well as the statin drugs. Excess cellular cholesterol gets fatty-acylated by the action of ACAT, to form cholesteryl esters for storage in cytoplasmic lipid droplets; the inverse reaction is controlled by, e.g., CEH.

14Cholesterol synthesis and HMGR activity in human as well as baboon placenta decrease as pregnancy progresses. There are estimates that de novo cholesterol synthesis in the term human placenta provides only 1–2% of the cholesterol required for progesterone biosynthesis. But the extent of cholesterol synthesis is species-specific; rabbit placentas near term exhibit a high level of HMGR expression and activity.

15Human pregnancy is characterized by maternal hyperlipidemia especially during the last trimester. High maternal estrogen concentrations and maternal insulin-resistance stimulate hepatic VLDL production. Triglyceride and cholesterol concentrations in LDL and HDL particles rise, providing ample cholesterol fuel for the STB. In contrast, maternal serum cholesterol levels in pregnant rabbits drop significantly compared to the non-pregnant state.

16With advancing gestational age, maternal serum-derived cholesterol replaces endogenously produced cholesterol as the major substrate of placental progesterone production in humans and baboons. Addition of LDL to primary trophoblast cultures drastically suppresses de novo cholesterol synthesis, stimulates progesterone production and inhibits cholesteryl ester-forming ACAT. Likewise, addition of HDL2 stimulates progesterone secretion in vitro. Trophoblasts isolated from healthy early, mid, and late baboon gestation show an upregulation of LDLR in mid and late gestation, while HMGR activity is reduced. Nevertheless, when external LDL supply is reduced in vivo or in vitro, human and baboon trophoblasts continue to produce sufficient progesterone due to endogenous cholesterol production. In choriocarcinoma cells, an inverse relationship between the lipoproteins in the culture medium and the HMGR activity was demonstrated. Together, these data suggest feedback inhibition of maternal-derived cholesterol on endogenous cholesterol synthesis and cholesteryl ester formation in human and baboon STB.

Impact of Exogenous and Endogenous Factors on Placental Cholesterol Biosynthesis

17Inconsistent with feedback inhibition by cholesterol, maternal hypercholesterolemia does neither change placental HMGR protein levels nor change placental cholesterol or cholesteryl ester content.

18From other tissues, age- and gender-related dysregulation of cholesterol metabolism, and specifically of HMGR regulation are known. A hint for placenta-specific regulation of cholesterol biosynthesis is the observation that maternal hypercholesterolemia causes an increase in the placental expression of the transcription factor SREBP-2. Scarce information is available on regulation of the placental SREBP – SCAP – INSIG system (Figure 3). In the Golden Syrian hamster, suppression of sterol synthesis by exogenous sterol is blunted in placenta and other developing tissues when compared to parental tissues. This lack of response appears to be mediated at least partly through the SCAP:INSIGs ratio, which is 1.8-fold greater in the placenta as compared to the adult liver. Neither in human nor baboon placenta regulation of these molecules has been investigated so far, but this topic might be of relevance in the context of ART, which are increasingly applied today. Among the observed adverse neonatal outcomes in pregnancies conceived through in vitro fertilization and intracytoplasmic sperm injection are low birth weight and small size for gestational age. Interestingly, a recent study performed in humans found that placenta and fetus from ART pregnancies showed altered transcript levels of INSIG1 and SREBF1. The enhanced gene expression correlated with lower methylation rates of INSIG1 and SREBF1. The authors hypothesized an impact of ART on the placental/fetal cholesterol metabolism with consequences for the future life of the offspring. More research is required to confirm this theory.

19Estrogen production is significantly (3–8 times at term) increased during pregnancy. The elevated estrogen levels were suggested to stimulate cholesterol uptake via increased LDLR expression as well as progesterone production via increased P450scc enzyme activity in cultured primary trophoblasts. In contrast, activities of the placental enzymes HMGR, ACAT, or CEH were found unaffected by estrogen. This contrasts with estrogen-influenced HMGR regulation in other species and tissues.

20Recently, an impact of GDM on cholesterol synthesis and esterification in isolated and cultured human placental endothelial cells (HPECs) has been observed. The authors of the study suspected that higher intracellular ROS levels in GDM upregulated HMGR, increased de novo cholesterol biosynthesis and ACAT1 expression, but the underlying mechanisms remain to be identified.

21Statins, inhibitors of HMGR, are increasingly prescribed to women of reproductive age, but in experiments with first trimester placental explants or isolated first trimester trophoblasts, statins revealed detrimental effects on trophoblast growth. Statins not only significantly decreased progesterone secretion. They also inhibited proliferation and migration of trophoblasts. Isoprenylation, which also depends on HMGR activity (Figure 3), is required for cell proliferation, migration, metabolism, and protein glycosylation and thus, proper development of embryo and placenta. The existing data suggest that statins should be avoided during the first trimester of pregnancy. On the other hand, there is evidence that statins, due to their anti-proliferative, anti-invasive, anti-inflammatory, and anti-angiogenic effects might be useful in treatment of various obstetric and gynecologic conditions including endometriosis, PCOS, ovarian cancer, preeclampsia, and antiphospholipid syndrome. Further studies are required to understand the mechanisms of action of statins during gestation. Moreover, clinical trials to investigate the efficacy, safety, and appropriate dosage of different statins during pregnancy are needed.

22In summary, the regulation of placental cholesterol synthesis requires further characterization, but species-specific placental structure and function should be considered. Many of the involved enzymes are regulated at multiple levels. Besides total mRNA and protein levels, DNA- and protein modifications and protein activities should be analyzed to obtain conclusive information about the mechanism of regulation. Since placental tissue is a mixture of different cell types, analysis of purified cell populations should be preferred over total tissue analysis to decipher cell type-specific regulation of protein expression.

Maternal Lipoprotein Particle Uptake by the STB

23Fetuses produce a significant fraction of the required cholesterol via endogenous synthesis. In humans, genetic defects in de novo cholesterol synthesis result in severe congenital birth defects. SLOS is caused by a deficiency of DHCR7 (Figure 3), which catalyzes the conversion of 7-DHC to cholesterol. SLOS fetuses with null mutations in DHCR7 exhibit no endogenous cholesterol synthesis, but they have some cholesterol in tissues and blood at birth indicating placental cholesterol transfer.

24Amount and period of materno-fetal cholesterol transport remain under debate. Extrapolation of data from non-human species is difficult as the quantity of cholesterol derived from the maternal circulation differs ranging from very low levels in rat to more than 40% in the rhesus monkey. Studies in humans revealed that materno-fetal cholesterol transfer occurred throughout pregnancy. However, mainly during early development maternal cholesterol serves as the primary source of fetal cholesterol.

25Subsequently, we summarize the mechanisms of placental cholesterol uptake and transport (Figure 4). Cholesterol transport across the secondary yolk sac that may participate in nutrition of the human fetus during the first trimester was reviewed elsewhere.

26In plasma, cholesterol is associated with different types of lipoprotein particles. Among them, LDLs carry 65–70% of circulating plasma cholesterol. Lipoprotein particles can interact with the plasma membrane of target cells via members of the LDLR family including LDLR, VLDLR, LRP1, LRP2 (megalin), or LRP8 (apoE receptor 2).

27The presence of LDL-specific binding sites was shown throughout pregnancy in preparations of microvillous placental membranes, representing enriched apical STB plasma membranes. Expression of LDLR mRNA in baboon STB increases with advancing pregnancy. Estrogen, but also depletion of cholesterol upregulate LDLR expression. But conflicting data concerning the regulation of LDLR mRNA levels in total placental tissue in the course of human pregnancy exist. Additional expression of LDLR in stromal cells in the chorionic villi and cell-type specific receptor regulation may account for that discrepancy.

28The transfer of lipids between HDL and target cells is incompletely understood. A number of proteins and receptors have been described to bind HDL. After receptor binding, HDL associated lipids are transferred to cells predominantly without catabolism of the particle. Transfer of cholesteryl esters to the accepting plasma membrane is known as “selective uptake”. An alternative pathway comprising endocytosis of whole HDL particles followed by resecretion exists. Neither the connection between HDL endocytosis and selective lipid uptake nor the physiological relevance of HDL uptake is fully clarified. SRB1 (in humans also termed CLA-1) is a multiple ligand receptor able to facilitate uptake of cholesteryl esters from HDL. SRB1 can also mediate whole HDL particle endocytosis.

29HDL binding-sites as well as SRB1 were found on isolated placental microvillous and basal plasma membranes of the STB. In situ, SRB1 localizes to first and third trimester trophoblasts as well as term pFECs. Cultured first trimester trophoblasts expressed SRB1, exhibited selective cholesteryl ester-uptake from HDL3, but also displayed considerable HDL endocytosis and degradation. In term cultured trophoblasts, SRB1 expression was lower. Likewise, selective uptake as well as HDL degradation were decreased compared to first trimester cells, but were still elevated compared to other tissues. In vitro, SRB1 involvement in selective cholesteryl ester-uptake from HDL3 was demonstrated. In total placental tissue highest SRB1 expression levels were observed in term placenta, which might be explained by the expression of SRB1 in pFECs and the increase of the proportion of vessels from 37% in first trimester to 63% at term. In pregnant women with high serum cholesterol levels, LDLR expression, but not SRB1 protein expression is down-regulated. Cell-type specific, SRB1 gene transcription can be regulated by hormones, including hCG and estrogen. Whether and how SRB1 expression in human STB and pFECs is influenced by these hormones, remains to be determined.

30VLDL binds to term placental microvillous membranes and the triglyceride-enriched VLDL is an important fatty acid supplier for the fetus. Hydrolysis of VLDL-associated triglycerides is mediated by lipases such as lipoprotein lipase, which are expressed at the apical membrane of the STB. While the placenta also expresses several receptors for apolipoprotein (Apo)E-enriched particles, including VLDLR, LRP1, LRP2, and LRP8, their involvement in cholesterol uptake by the STB has never been demonstrated. A mutation in human LRP2 gives rise to severe congenital anomalies in the offspring. This may indicate an important role of LRP2 in placental cholesterol transport, but LRP2 is a multiligand receptor and thus, may serve different roles in trophoblast biology.

Impact of Diseases and Exogenous Compounds on Placental Lipoprotein Receptor Expression

31GDM is a glucose intolerance, which is first recognized during pregnancy, but usually resolves after birth. In Europe, it has a prevalence of 5.4%. The most common adverse outcome is high fetal birth weight (macrosomia). Placental abnormalities include increased incidence of villous immaturity, increased measures of angiogenesis, and higher placental weight. GDM is also associated with a higher risk of maternal and fetal complications including development of type 2 diabetes in later life. In GDM, altered maternal and neonatal lipid profiles were observed. Moreover, expression of LDLR and SRB1 was induced.

32IUGR is observed in 5–10% of pregnancies. Due to a compromised placental function, the fetus does not reach its intrauterine potential for growth and development. As the second leading cause of perinatal mortality IUGR is responsible for 30% of stillborn infants. Long-term health defects include impaired neurological and cognitive development and cardiovascular or endocrine diseases in adulthood. IUGR is associated with a decreased supply of nutrients and/or oxygen to the growing fetus. Placental LDLR expression was found increased, while SRB1 expression was decreased compared to healthy controls.

33Preeclampsia is a multifactorial pregnancy-specific disease affecting 3–5% of pregnancies. It is defined by de novo hypertension manifested after 20 weeks of gestation in combination with either proteinuria (300 mg/day), maternal organ dysfunction or uteroplacental dysfunction. IUGR and premature birth are clinically relevant complications. In addition, preeclampsia affects the long-term outcome of both mothers and their offspring. Serum levels of triglycerides, LDLs, small dense LDLs that are susceptible to oxidation, as well as oxLDLs are higher in women with preeclampsia compared to healthy pregnant women. found decreased expression of VLDLR and LDLR mRNA in third trimester placentas derived from preeclamptic women. reported no differences in LDLR, LRP1, SRB1 mRNA levels when comparing placentas of healthy and preeclamptic women. But they observed reduced LRP1 mRNA expression in placentas of preeclamptic mothers delivering small-for-gestational-age babies compared to healthy controls.

34Maternal exposure to cadmium, which is present in tobacco smoke, is associated with low birth weight and possibly with an increased incidence of spontaneous abortion. Cadmium accumulates in the placenta and reduces progesterone secretion. Partly, this is related to a down-regulation of LDLR mRNA.

35In summary, the human placenta expresses several receptors for lipoprotein particles. For most receptors, their involvement in and individual contribution to placental cholesterol uptake remains unexplored. Moreover, regulation of receptor expression under physiologic and pathologic conditions of pregnancy has been barely investigated.

Intracellular Cholesterol Transport in the STB

36After internalization into acidic endosomal compartments, dissociation of receptor-ligand complexes occurs. The receptors return to the plasma membrane, while lipoprotein particles enter the lysosomal route for degradation. Cholesterol incorporates into the endosomal/lysosomal membranes by coordinated actions of NPC1 and NPC2. Cholesterol transport to mitochondria for steroidogenesis is achieved by lipid transfer proteins including StAR/STARD1 and other members of the START domain protein family. Cholesterol transport to other cellular targets, e.g., the plasma membrane occurs by vesicular and non-vesicular means, the latter involving cholesterol binding to various proteins. Although expression of some intracellular cholesterol transporting proteins including NPCs, NPC1-Like1, ABC-transporters ABCA2, SCP-x, STARD3, and HSP60 has been demonstrated in human term placenta, the mechanism of intracellular cholesterol transport in STB remains largely uncharacterized.

Cholesterol Exit From the STB

37To eliminate cholesterol, hepatocytes secrete lipoprotein particles. Secretion requires ApoB and the ER-localized cofactor MTP. MTP transfers lipids to the forming lipoproteins. It is a dimer of a 97-kDa protein and PDI. Most other cell types release excess cholesterol to extracellular lipid acceptors. Mechanisms accounting for cholesterol efflux include passive diffusion as well as active pathways mediated by ABCA1, ABCG1, and SRB1. Several factors including cellular cholesterol status, lipid transporter activity, and the nature of extracellular acceptors, influence the efficiency of cholesterol efflux. ABCA1 and ABCG1 are specifically important for the elimination of cholesterol from cells and tissues and for the biogenesis of HDL. ABCA1 stimulates cholesterol efflux to lipid-free apolipoproteins, predominantly to apoA-I, but also ApoE. In contrast, ABCG1 promotes efflux of cholesterol and oxysterols to HDL. SRB1 can mediate cholesterol efflux from peripheral cells to HDL, but not to lipid-free apoA-I.

38Efflux of cholesterol from the basal side of the STB is unclear. It may occur via secretion of either lipoprotein particles or of cholesterol complexed with apolipoproteins. ApoB, MTP large subunit and PDI are expressed in the STB and unique lipoprotein particles containing ApoB and ApoA-I have been isolated from placental tissue. Furthermore, secretion of ApoB-100-containing lipoprotein particles was shown from term placental biopsies. More recently, apical and basal secretion of ApoB in polarized grown BeWo cells was demonstrated. Cholesterol complexed with ApoB or lipoprotein particles and secreted from the basal membranes of the STB could provide cholesterol and other lipids not only to pFECs and consequently to the fetus, but also to CTBs as well as stromal cells of the chorionic villi given that these cells express the relevant apolipoprotein receptors. Indeed, in situ expression of lipoprotein receptors such as LDLR or LRP1 on placental cells including pFECs or LRP2 on the CTB was shown. This would enable uptake of STB-derived lipoprotein-associated cholesterol. In support of the idea that intact lipoproteins reach stromal cells of the villi, a capability to hydrolyze VLDL-triglycerides has been demonstrated on isolated placental macrophages. However, how placental macrophages or other stromal cells cover their cholesterol requirements is currently unknown.

39Apical secretion of ApoE from the STB was suggested to facilitate uptake of maternal non-LDL lipoprotein particles; likewise, apical secretion of ApoB, which was observed in BeWo cells, could be of relevance for regulation or induction of cholesterol uptake by trophoblasts. Moreover, apical secretion of apolipoproteins may enable RCT from the STB via apically expressed ABCA1 or SRB1 (see below). However, these speculations require further investigation.

40Alternatively, cholesterol can exit the STB via ABCA1 and ABCG1, which stimulate efflux of cholesterol and oxysterols. Both transporters exhibit high expression in the placenta. They localize to apical (ABCA1) and basal membrane (ABCG1) of the STB and to the luminal surface of the pFEC, but contradictory localization data also exist. In cultured trophoblasts, up- or down-regulation of ABCA1 and ABCG1 stimulated or reduced, respectively, cellular cholesterol efflux. The presence of SRB1 at the apical and basal membrane of the STB would allow for bidirectional transport of liposoluble molecules to and from lipoprotein particles. In polarized grown BeWo cells, basal efflux of cholesterol was highest to HDL, and was suggested to occur via either SRB1, or ABCG1. However, expression and subcellular localization of SRB1, ABCA1, and ABCG1 seem to differ between BeWo cells and primary trophoblasts. In any way, an efflux of cholesterol from the basal membrane of the STB via ABCG1 or SRB1 requires appropriate cholesterol acceptor molecules within the stroma of the villi. This has not been described.

Cholesterol Transport by pFECs

41Uptake of cholesterol by pFECs remains unknown. Efflux of cholesterol via ABCA1 and ABCG1 to apolipoproteins or HDL particles, respectively, has been confirmed in isolated term HPECs, while SRB1 does not contribute to HDL-mediated cholesterol release. Appropriate cholesterol acceptor molecules (HDL and ApoE) are available in the fetal circulation.

Regulation of ABC-Transporters via LXR in Health and Diseases

42LXRs are “sterol sensors” responsible for protecting cells from cholesterol overload. LXR-activation by oxysterols (see below), but not cholesterol, induces transcriptional activity of the LXR/RXR heterodimer. This results in reduced intracellular cholesterol synthesis as well as cholesterol uptake, but induced expression of molecules implicated in RCT including ABCA1, ABCG1, and ApoE (;; see Figure 3). Although oxysterols are generally perceived as endogenous agonists of LXR, some can act as antagonists. Due to their role in lipid metabolism, LXRs are considered as relevant drug targets. The synthetic ligands T0901317 and GW3965 are important tools in biomedical research. Unfortunately, they have poor LXR subtype selectivity and T0901317 is not only an LXR ligand, but also displays agonistic effects on farnesoid X receptor and pregnane X receptor.

43LXR-α and LXR-β as well as RXR can be detected throughout gestation, with increased expression of LXRs in preterm and term placentas. Preeclampsia or GDM were found to influence expression of LXRs in some, but not all studies.

44LXR controls expression of ABCA1 and ABCG1 in cultured trophoblasts and HPECs. Oxysterols or T0901317 increase cholesterol efflux, while LXR-inhibitors or siRNA-mediated LXR knock down decrease cholesterol efflux. As key regulators of the lipid metabolism, LXRs also play a regulatory role in fatty acid metabolism in trophoblast cells.

45Recently, upregulation of ABCA1 and ABCG1 in HPECs derived from GDM placentas compared to control placentas was shown. Upregulation was the consequence of GDM-induced increased ROS-formation, increased ROS-derived oxysterol levels and subsequent LXR activation. The resulting enhanced cholesterol efflux protected the cells from cholesterol overload due to GDM-induced increased cholesterol biosynthesis. Thus, the LXR-mediated upregulation of ABC-transporters in GDM appeared to restore cholesterol homeostasis. Alterations of expression levels of ABCA1 and ABCG1 in total placental tissue in case of pregnancy diseases such as GDM, preeclampsia, hypoxia, or antiphospholipid-syndrome were reported, but the results are partly inconsistent.

46ABCA1 and ABCG1 also efflux oxysterols. In cultured trophoblasts, both transporters were shown to prevent accumulation of the oxysterols 25-hydroxycholesterol (25-OHC) and 7-ketocholesterol (Figures 2C,E), which exhibit cytotoxic potential at higher concentrations. ABCA1 expression increases during trophoblast syncytialization in vitro. ABCA1 localization at the apical STB membrane in situ (Figure 4) may ensure efflux and thus placental elimination of oxysterols into maternal blood.

Oxysterols and Pregnancy

47Many different oxysterols have been identified; they are formed by either free radical oxidation or by enzyme-mediated mechanisms. Oxysterols exhibit multifaceted functions. Some oxysterols are important regulators of cholesterol homeostasis (Figures 3, 4). 27-OHC (Figure 2D), produced from cholesterol by the enzyme CYP27A1, is the most prominent oxysterol in the bloodstream of human adults. In vitro, 27-OHC inhibits cholesterol synthesis by negative feedback regulation of HMGR. 27-OHC is an agonist of LXR stimulating cholesterol efflux from cells. Increased CYP27A1 and/or 27-OHC levels might reflect the attempt to remove excess cholesterol from cells and to limit lipid peroxidation. Some studies show that diseases of pregnancy such as preeclampsia are associated with altered expression of placental CYP27A1 protein and altered levels of 27-OHC in placenta, maternal, and/or fetal serum. But these studies are partly contradictory and the mechanism behind the alteration and the impact of these changes on placental cholesterol metabolism remains to be determined.

48Oxysterols are major components of oxLDL. They contribute to the pathophysiology of atherosclerosis, and are found at increased levels in atherosclerotic lesions. OxLDL serum levels rise even during normal gestation. Elevated levels of oxLDL and oxysterols have been identified in maternal serum in preeclampsia, pregnancy-induced hypertension, GDM, and diabetes mellitus type I as well as in the cord blood of neonates with IUGR or GDM. Overall, the cytotoxic and pro-inflammatory activities of oxysterols contribute to the development of many diseases associated with oxidative stress.

49Oxysterols can influence various aspects of trophoblast function. The oxysterols 25-OHC and 7-keto-cholesterol (Figures 2C,E), which are present in oxLDLs, reduce trophoblast invasion via activation of LXR. Moreover, 25-OHC inhibits syncytialization of CTB. Oxysterols increase the release of soluble endoglin, a molecule present at elevated concentrations in the maternal circulation in women with preeclampsia, via increased expression of matrix metalloproteinase 14 in the placenta. Oxysterols promote the production of pro-inflammatory cytokines in placental trophoblasts, via activation of TLR 4 thus providing a mechanistic link between oxidative stress in pregnancy and placental inflammation. This pro-inflammatory action of oxysterols predominated over simultaneously observed anti-inflammatory effects mediated by oxysterols via LXR activation. It has been speculated that LXR activation indirectly supports the repression of TLR target genes activation. LXR activation results in increased placental expression of ABCA1 and ABCG1. This may change cellular oxysterol levels as well as alter the cholesterol content of the membrane microdomains required for TLR signaling by promoting cholesterol efflux.

50The dual (pro-inflammatory/anti-inflammatory) role of oxysterols observed in trophoblast cells already indicates the complexity associated with these molecules. In addition, a study by revealed that the effects of oxysterols on trophoblasts are concentration dependent. 25-OHC applied at higher (100 μM) concentrations was found to be cytotoxic, to inhibit differentiation as well as progesterone secretion of trophoblast cells. In contrast, low (10 μM) concentrations stimulated differentiation, progesterone secretion and ABCA1 expression, and reduced SRBP2, LDLR and HMGR expression. To add to the complexity, not all of these cellular effects are mediated via LXR. Oxysterols are known to interact with many proteins. RORα and RORγ are other nuclear receptors binding oxysterols. RORs are transcription activators and RORγ was shown to regulate hepatic lipid metabolism. Loss of RORγ reduces the expression of a number of lipid metabolic genes, which in turn reduces the levels of triglycerides, cholesterol, and bile acids in liver and blood. 25-OHC is an agonist of RORγ, while other oxysterols may function as inverse agonists. Oxysterols including 25-OHC are able to bind INSIGs, which induces interaction of INSIGs and SCAP and consequently inhibits SREBP activation. 25-OHC can regulate cholesterol synthesis by interaction with NPC1 and 2. Finally, 25-OHC can bind to OSBP and ORPs and modify their function (Figure 3). ORP8 can modulate ABCA1 expression and thereby influence cholesterol efflux.

51To conclude, oxysterols can compromise placental formation, regeneration, and function, but also are important regulators of placental cholesterol metabolism and probably other physiological processes. Their effect may depend on the identity and concentration of the local oxysterol compound and the available intracellular binding partners. ABCA1 and ABCG1 were shown to prevent the toxic effects of oxysterols on placental and fetal development and function, and reduce the risks associated with diseases of pregnancy such as GDM. But altered regulation of these receptors or oxysterol binding partners in the case of pregnancy-associated diseases in combination with increased levels of oxysterols might (further) compromise placental function.

52Our knowledge of function and regulation of oxysterols in the context of pregnancy and regulation of cholesterol metabolism remains limited. We need to explore the types of oxysterols induced during healthy and diseased pregnancy, and learn whether they are generated mainly by enzymes or by autoxidation. It remains to be determined whether they act primarily early (around implantation) or late in pregnancy. Published data are often contradictory. This might be related to problems associated with reliable measurements of oxysterols that are quite susceptible to autoxidation and the fact that oxysterol production is influenced by several factors including cell type, mode of experimentation or circadian variations.

Steroid Hormones

53Steroid hormones comprise sex steroids and corticosteroids. In adults, the sex steroids – progestagens, estrogens, and androgens – are produced in ovaries and testes, while the corticosteroids – glucocorticoids and mineralocorticoids – are released from the adrenal cortex. During pregnancy, the placental STB becomes a major source of progesterone (at term around 250 mg/day) and estrogens (at term around 100–120 mg/day). Fetal organs (adrenal cortex and liver), in contrast, synthesize corticosteroids and the androgens DHEA, DHEA-S, 16α-hydroxy-DHEA, and 16α-hydroxy-DHEA-S. These hormones are transfered between placental and fetal compartment and are subjected to transformation. Partly, fetus and placenta have complementary enzyme activities and thus are interdependent. Moreover, the hormones also reach the maternal compartment. For more information about steroid hormone exchange between fetus, placenta and mother the reader is referred to. Proper function and interaction of the steroid producing tissues and the involved enzymes and transporters is crucial since the intrauterine exposure of the offspring to abnormal levels of glucocorticoids or sex steroids can negatively impact fetal development. Furthermore, abnormal concentrations of steroid hormones during pregnancy can increase the maternal risk for malignant diseases. The following chapters summarize the mechanisms of uptake, synthesis, and transformation of steroid hormones at the human placental barrier and highlight circumstances that cause alterations.

54Steroid hormones are derived from cholesterol and thus have closely related structures based on the common steroid skeleton (Figure 2A). The major classes of enzymes required for the production of steroid hormones are the CYP heme-containing proteins (P450 and CYPs) and the HSDs. CYPs important for steroid hormone synthesis are CYP11A1, which is a mitochondrial protein, as well as CYP17A1, CYP19A1, and CYP21A2, all located in the ER. CYPs catalyze the hydroxylation and cleavage of steroid substrates, while reduction and oxidation of steroid hormones are effected by isoforms of 3βHSDs and 17βHSDs. Cell-type specific, HSDs localize to the membranes of either mitochondria or ER. The major placental transporter families are SLCs and the ABC-transporters. SLCOs usually mediate influx of their substrates. They participate in uptake of hydrophilic or charged molecules such as sulfated steroids. In contrast, ABC-transporters mediate the efflux of substrates.

Progesterone

55Progesterone (P4) is the major and most relevant progestagen. In humans, the ovarian corpus luteum secretes progesterone until week 8 of gestation, thereafter, the placenta completely takes over the production.

56Progesterone exerts many functions. Briefly, it is an intermediate in the production of other steroid hormones (Figures 5, 6) and a neurosteroid involved in brain function. Progesterone is crucial for a successful pregnancy as it supports blastocyst implantation, maintains pregnancy, and prepares the mammary glands for lactation. Progesterone and synthetic progestins are successfully used for the prevention of preterm birth and for treatment of various gynecological disorders.

57The action of progesterone on target tissues is mediated by two progesterone receptor isoforms (A and B) that function as ligand-activated transcription factors. Under physiological conditions, the withdrawal of progesterone receptor-mediated signaling triggers menstruation and parturition. Likewise, pathologic deregulation of the progesterone-receptor signaling pathway is associated with preterm delivery. For example, poor pregnancy outcome due to hepatitis E virus infection is related to low expression of functional progesterone receptors and high expression of receptor haplotypes exhibiting reduced response to progesterone.

Physiology and Pathophysiology of Progesterone Synthesis

58Synthesis of progesterone starts within mitochondria (Figures 4, 6). Cholesterol has to be loaded into the outer mitochondrial membrane in a process that is not entirely understood. In most steroidogenic tissues, the transport of cholesterol from the outer to the inner mitochondrial membrane is mediated by StAR, which can be acutely stimulated by tissue-specific trophic hormones; however, StAR is not expressed in human placenta. Instead, StAR-like protein, STARD3 (or MLN64) as well as HSP60 are involved in mitochondrial cholesterol import in the placenta. In JEG-3 cells, HSP60 additionally participates in delivery of cholesterol to the metabolizing enzyme CYP11A1. STARD3 action requires a complex multicomponent molecular machine on the outer mitochondrial membrane, which includes, among other factors, the translocator protein TSPO. In obese women (BMI 38.8 ± 6.4 kg/m2), who exhibit altered insulin sensitivity and leptin level, the serum levels of progesterone as well as estradiol were significantly reduced. While expression of key enzymes of placental progesterone and estrogen synthesis (CYP11A1, 3β-HSD1, and 17β-HSD1) was not altered, the expression levels of TSPO as well as the cholesterol content in placental mitochondria were decreased. In vitro, long chain fatty acids and LPS could reduce TSPO expression.

59After mitochondrial import, cholesterol is hydroxylated at two positions (C-20 and C-22) and the cholesterol side chain is cleaved off by P450 side-chain cleaving enzyme (P450scc or CYP11A1; Figures 5, 6;; ). CYP11A1 is a rate-limiting enzyme of steroidogenesis and converts cholesterol to pregnenolone, the precursor of all other steroid hormones. Moreover, CYP11A1 is also a metabolizing enzyme for other sterols. It mediates conversion of 7-DHC to 7-dehydropregnenolone and hydroxylates the side chain of vitamin D.

60CYP11A1 localizes exclusively to the STB. The placental CYP11A1 protein expression level remain constant from first to term trimester. The major regulatory factor for CYP11A1 gene expression in other steroidogenic tissues, SF-1, is absent in the human placenta. Instead, human placental CYP11A1 gene expression is tightly regulated by one activator (LBP-1b) and two repressor proteins (LBP-9 and LBP-32). In analogy to CYP11A1, these proteins are expressed already very early in pregnancy and localize to the STB.

61CYP11A1 is upregulated at both mRNA and protein level in placentas of women with severe preeclampsia. Overexpression of CYP11A1 reduces trophoblastic cell proliferation and induces apoptosis in the HTR8/SVneo extravillous trophoblast cell line through activation of caspase-3 expression. In line with increased expression of CYP11A1 during preeclampsia, the level of pregnenolone (and progesterone) is increased in preeclamptic women. CYP11A1 is also involved in lipid peroxidation. Based on results obtained in isolated placental mitochondria and JEG-3 cells, it has been speculated that not only excess progesterone synthesis but also production of lipid peroxides by increased expression of placental CYP11A1 may contribute to the pathogenesis of preeclampsia.

62In contrast, life style factors like smoking or cocaine may inhibit progesterone synthesis. Cadmium, which is found in cigarette smoke, reduces CYP11A1 mRNA expression as well as progesterone synthesis in human cultured trophoblasts. A study in pregnant rats treated with cocaine demonstrated significantly reduced maternal serum levels of pregnenolone and progesterone as well as reduced mRNA and protein expression of CYP11A1 and STARD3.

63Pregnenolone is converted to progesterone by 3β-HSD1 in the ER (Figures 5, 6;; ). 3β-HSD1 is exclusively expressed in the placental STB, while 3β-HSD2 is predominantly expressed in the adrenal gland and gonads. Besides pregnenolone, human 3β-HSD1 can also use 17α-hydroxypregnenolone and DHEA as substrates. Various endogenous hormones including estradiol, insulin, insulin-like growth factor, calcitriol, leptin, and CRH can modulate progesterone synthesis. Unfortunately, also environmental toxins influence activity of 3β-HSD1 and thus progesterone synthesis. Evidence for this was obtained in the choriocarcinoma cell line JEG-3. Fine PM (<2.5 μm, PM2.5) is a leading air pollutant and exposure to PM2.5 during the prenatal period increases the risk of adverse pregnancy outcome. Exposure of cells to PM2.5 causes reduced progesterone secretion as well as reduced expression of 3β-HSD1 and CYP11A1 mRNA and protein. The fungicide tributyltin lowers progesterone production and acts as a moderate inhibitor of 3β-HSD1. Likewise, the insecticides methoxychlor and its metabolite hydroxychloroquine inhibit progesterone as well as estradiol production; these substances are potent 3β-HSD1 inhibitors. In contrast, ochratoxin A, a common food-borne mycotoxin, induces the expression of 3β-HSD1, leading to a significant increase of progesterone production.

Estrogens

64The group of estrogen steroids comprises estrone (E1), estradiol, (E2), estriol (E3), and estetrol (E4). Among these, estradiol is the most abundant estrogen. Estrogen’s multiple functions have been summarized on several occasions and include stimulation of utero-placental blood flow, endometrial growth and differentiation, contraction of the myometrium and proliferation of the mammary epithelium. As detailed in the chapter on cholesterol, estrogens also regulate expression of genes required for placental cholesterol supply. They exert their effect via different types of receptors, the nuclear estrogen receptors α and β as well as membrane-associated receptors. The synthesis of estrogens is controlled by diverse endogenous hormones such as estradiol, cortisol, calcitriol, CRH, hCG, insulin, and leptin.

Physiology and Pathophysiology of Estrogen Synthesis

65Synthesis of estrogens involves several enzymes and transporters (Figures 5, 6). CYP17A1 (or P450c17) is a bifunctional enzyme with 17α-hydroxylase and 17,20-lyase activities that converts pregnenolone to 17α-hydroxypregnenolone and subsequently to DHEA. Alternatively, progesterone can be converted to 17α-hydroxyprogesterone (17α-OHP) and then to A-dione. Early studies in human placentas and choriocarcinoma cell lines could not demonstrate placental CYP17A1 activity or mRNA expression. The concept emerged that the placenta was unable to convert pregnenolone and progesterone to the androgen products. Thus, compulsive import of sulfated fetal C19-androgens, 16α-hydroxylated DHEA-S and DHEA-S, which are further processed into estrogens by placental STS, 3βHSD1, CYP19A1 (aromatase), and 17βHSD isoenzymes, was assumed. However, more recent studies demonstrated placental CYP17A1 mRNA expression, although at a much lower level as compared to 3β-HSD1, CYP19A1, CYP11A1, and 17β-HSD3. CYP17A1 protein was detected in placental STB and JEG-3 cells. 17α-OHP synthesis by CYP17A1 in trophoblasts is regulated by the cAMP/PKA pathway. The authors estimated that 20–30% of the estrogen produced during pregnancy could result from pregnenolone conversion by placental CYP17A1.

66While endogenous production of DHEA in the STB occurs, a large fraction of the sulfo-conjugated C19-estrogen precursors 16α-OH-DHEA-S and DHEA-S is derived from the fetus (Figure 6); maternal DHEA-S is also used, but to a minor extent. DHEA is produced in the fetal adrenal gland, which is also rich in SULT activity, thus generating DHEA-S. 16α-OH-DHEA-S, that is the most abundant estrogen precursor, is synthesized in the fetal liver by 16α-hydroxylation of DHEA-S via CYP3A7. Fetal hepatic CYP3A7 expression is detected around day 50 to 60 of gestation; expression of CYP3A7 in human placenta remains unclear. Unconjugated estrogens, synthesized by the placenta, are released into both the maternal and fetal blood by diffusion. In part, they get sulfated in the maternal and fetal compartment and re-enter the placenta by carrier-mediated transport (see below). Moreover, the human placenta exhibits STS activity as well as SULT activities (e.g., SULT1E1 and SULT2B1) and thus can convert unconjugated estrogens (or other substrates) into sulfated forms and vice versa, respectively. For more information on the function of sulfated steroid hormones in reproduction, the reader is referred to.

67Uptake of conjugated fetal and maternal steroids requires placental expression of appropriate transport systems. The human SLC family 22 member 11 (SLC22A11) also known as OAT4, is predominantly expressed in placenta and kidney. In placenta, OAT4 was detected at the basal plasma membrane of the STB as well as on the CTB in first- and third-trimester placentas. Studies using isolated basal membrane fractions of placental STB, primary trophoblasts, JEG-3 cells as well as OAT4-transfected cell lines demonstrated uptake of sulfated steroids, including DHEA-S, 16α-OH-DHEA-S and sulfated estrogens via OAT4. PKA regulates OAT4-mediated transport of sulfated steroids. The SLC OAT family member 2B1 (SLCO2B1, OATP2B1, and OATP-B) is also expressed at the basal surface of the STB and on the CTB. However, 16α-OH-DHEA-S is not a substrate of SLCO2B1. SLCO2B1 can transport sulfated estrogens, while conflicting data exist about whether DHEA-S is a substrate of this transporter. SLCO2B1 activity is regulated by unconjugated steroid hormones. The BCRP (ABCG2) is found on the apical surface of placental STB. Placental ABCG2 appears regulated by several endogenous factors (including hormones) as well as exogenous factors. In ABCG2/OATP2B1-overexpressing epithelial MDCKII cells, obtained evidence that OATP2B1 and ABCG2 together mediate basolateral-to-apical directed transport of the steroid sulfates E3-S and DHEA-S. Thus the current concept for uptake of fetal sulfated steroid is that OAT4 can transport sulfo-conjugated estrogens as well as sulfated C19-steroid precursors for placental de novo synthesis of estrogens. In contrast, OATP2B1 (in combination with ABCG2) may rather contribute to the clearance of estrogen sulfates (as well as DHEA-S?) from the fetal circulation. SOAT was identified as transporter for both 16α-OH-DHEA-S and DHEA-S. SOAT was detected in the apical membrane of STB as well as on pFECs in the third trimester of pregnancy. This transporter may thus mediate uptake of fetal 16α-OH-DHEA-S and DHEA-S by pFECs and maternal DHEA-S by the STB. A mechanism for exit of sulfated steroids at the abluminal side of pFECs is unknown (Figure 6).

68STS, also known as aryl sulfatase C is responsible for hydrolysis of steroid sulfates such as DHEA-S, 16α-OH-DHEA-S, E1-S, E2-S, and E3-S, leading to the production of their unconjugated active forms. STS is expressed in the STB and STS mRNA and protein is significantly elevated in placentas from early onset preeclamptic women. In preeclampsia, anti-angiogenic factors such as soluble fms-like tyrosine kinase (sFlt)1 disrupt the maternal endothelium by binding circulating angiogenic factors, which causes the symptomatic second stage of preeclampsia including dysregulated placental perfusion and ischemia. Silencing of STS in primary placental trophoblasts resulted in a significant decrease in sFlt1 secretion and a significant reduction in sFlt1 transcription. Thus, it was speculated that high STS expression could contribute to preeclampsia via altered sFlt1 regulation.

693β-HSD1 catalyzes the conversion of DHEA into A-dione, which is further transformed to estrone by the P450 aromatase (CYP19A1). CYP19A1 could also convert testosterone into estradiol, but affinity of CYP19A1 for A-dione is much higher. Placental CYP19A1 expression and function are diminished in pregnancies complicated by preeclampsia compared to controls. PCOS is a common endocrinal metabolic disorder, affecting approximately 5–10% of women at reproductive age. It is characterized by ovulatory/menstrual irregularity, polycystic ovaries, and hyperandrogenism, including progesterone resistance. In placental tissue from women with PCOS, reduced activities of CYP19A1 and increased activities of 3β-HSD1 were observed when compared to control women. Moreover, women with PCOS showed higher A-dione and testosterone concentrations compared to normal pregnant women.

7017β-HSDs are also known as 17-ketosteroid reductases. They catalyze the reversible conversion of 17-keto and 17β-hydroxy groups in androgens and estrogens, including A-dione, DHEA, and estradiol. The direction of the reaction depends on the substrate. 17β-HSD1 predominantly catalyzes the NADPH-promoted stereospecific reduction of estrone to the more active estradiol. 17β-HSD2 shows oxidative activity and is capable of catalyzing the conversion of estradiol, testosterone, and dihydrotestosterone to their less-active 17-keto forms, estrone, A-dione, and 5α-androstanedione, respectively. These two enzymes were found to have different locations in the placenta. While 17β-HSD1 was detected in the STB already at week 4 of gestation, 17β-HSD2 was expressed in the pFEC and detected only after week 12 of gestation. 17β-HSD2 was suggested to prevent the excessive passage of active estrogens into the fetal circulation by catalyzing the inactivation of estradiol to estrone within the pFECs. Placental expression of 17β-HSD3, which is involved in testosterone formation, is increased in preeclamptic women. 17β-HSD5 protein and 17β-HSD7 mRNA expression were shown in human placenta.

71Estriol is mainly synthesized from 16α-OH-DHEA-S, but, alternatively, can be converted from estrone or estradiol. This requires expression of enzymes with 16α-hydroxylase activity such as CYP1A1 (; Figure 6).

72Overall, in preeclampsia, and specifically early onset preeclampsia, several of the placental enzymes involved in progesterone and estrogen formation and transformation show altered expression. Moreover, the placental expression levels of steroid receptors (estrogen receptor α and β, progesterone receptor) can change in preeclampsia. Whether the alterations are a consequence of preeclampsia or precede the disease is not known. Maternal serum progesterone and estrogen levels are found reduced, while androgen levels are increased in preeclampsia. But data remain partly conflicting, which might be due to diverging characteristics of the patients selected.

73Most of the reports are mainly descriptive without any analysis of mechanisms causing the underlying changes. One exception is a recent study describing a significant up-regulation of microRNA (miR-22) in placentas derived from preeclamptic women. MicroRNAs (miRNAs) are small non-coding RNAs of about 22 nucleotides in length that play a critical role in post-transcriptional gene regulation. The authors demonstrated significantly increased testosterone and reduced estradiol levels in plasma samples as well as increased placental expression levels of 17β-HSD3 and reduced placental aromatase expression in women with early onset preeclampsia. Furthermore, increased levels of the miR-22 were detected mainly in placental villous and extravillous trophoblasts. JEG-3 cells were then used to explore the mechanism behind the changes. Increasing testosterone concentrations repressed the expression of aromatase and estrogen receptor α and the production of E2. Testosterone caused increased miR-22 expression, which directly inhibited estrogen receptor α expression. The altered estrogen receptor α signaling decreased aromatase expression and estradiol production. Unfortunately, the question how 17β-HSD3 is induced by preeclampsia remains open. 17β-HSD1 also appears dysregulated – albeit significantly reduced – in preeclamptic placentas, most likely due to upregulation of miR-210 and miR-518c, which were confirmed to target 17β-HSD1. Dysregulation of miRNAs in preeclamptic placentas has also been reported by and.

74The adrenocortical carcinoma cell line NCI-H295R is an established cellular model to study adverse effects on steroidogenesis of numerous substances including heavy metals such as cadmium or industry-derived environmental toxins such as perfluoroalkyl acids. Various substances have already been found to change steroid production and thus it might be expected that these molecules could also impact placental steroidogenesis. For cadmium, this has already been demonstrated, but further functional studies are required. In this context the recently established co-culture models of choriocarcinoma cells (JEG-3 or BeWo) with H295R cells should be considered for future analysis. The H295R/BeWo co-culture model offers the opportunity to evaluate the effects of chemical exposures on androgen and estrogen biosynthesis, as well as on various other aspects of feto–placental communication.

Glucocorticoids and the Placenta

75Glucocorticoids or glucocorticosteroids are produced by the adrenal cortex in response to cues such as stress or illness under the control of the HPA-axis. The name glucocorticoid is derived from their ability to promote gluconeogenesis in the liver and their synthesis in the adrenal cortex. The natural human glucocorticoid is cortisol (Figure 7). In the adult, these signals stimulate the hypothalamus to release CRH, which in turn cause the release of ACTH from the anterior pituitary. ACTH induces synthesis of glucocorticoids from cholesterol in the adrenal glands, which exerts a negative feedback on the release of CRH and ACTH (Figure 8).

76Glucocorticoids coordinate many functions such as inflammatory and immune responses, metabolic homeostasis, cognitive function, reproduction, and development. At the cellular level, glucocorticoids exert their effects by binding to the GR that is almost ubiquitously expressed and induces target gene transcription. The classical model of GR transactivation involves GR dimerization and binding at glucocorticoid response elements (GREs) leading to co-activator recruitment and activation of transcription from proximate promoters. GR is expressed in STB and CTB as well as in JEG-3 and BeWo cell lines. Cortisol stimulates productions of placental hormones such as CRH and hCG. Increased cortisol levels in the placenta are linked to the induction of estrogen synthesis, which precedes the onset of parturition in human. Induction of CYP19A1 in trophoblast cultures in response to cortisol was shown to occur via activation of the cAMP/PKA pathway by CRH and hCG and the subsequent induction of transcription factor Sp1 (,; Figure 8).

Placental CRH Synthesis and Function

77CRH is the major mediator of adaptive response to stressors and is synthesized by several organs. During pregnancy, the CRH concentration in maternal plasma increases substantially and reaches levels that are 1,000–10,000 times that of non-pregnant women. The major CRH source during pregnancy is the placenta that can also produce ACTH. CRH is synthesized in the STB from first to third trimester. In humans and great apes CRH levels rise exponentially throughout pregnancy to peak at labor. Rodents, in contrast, do not exhibit placental CRH production. Placental CRH production may have evolved in primates to stimulate fetal ACTH release and adrenal steroidogenesis, in order to guarantee sufficient synthesis of DHEA, a precursor for placental sex hormone synthesis. Concomitant stimulation of fetal cortisol and DHEA by placental CRH would couple the glucocorticoid effects on fetal organ maturation with the timing of parturition. While glucocorticoids inhibit hypothalamic CRH synthesis and secretion, they paradoxically stimulate placental CRH expression.

78CRH operates via activation of two receptors, CRH-receptor type 1 and type 2, which are expressed in the human placenta. Placental CRH exhibits many functions in pregnancy and parturition. To name a few, CRH modulates placental glucose transporter expression and stimulates estradiol production by induction of STS, CYP19A1, and 17β-HSD1 expression in trophoblasts. CRH impacts on the expression levels of several other placental hormones including ACTH and prostaglandin. Progesterone is an inhibitor of CRH production and also a competitive antagonist of cortisol binding to GR. On the other hand, CRH inhibits progesterone production by suppression of CYP11A1 and 3β-HSD1. CRH is involved in the timing of birth by regulation of estrogen and progesterone levels as they control the contractile properties of the myometrium.

Placental Cortisol Metabolism and Transport in Health and Disease

79Glucocorticoids are important during pregnancy and for fetal development. Fetal glucocorticoid synthesis is only partially influenced by the HPA axis, but instead is primarily regulated by differential expression of the enzymes required for glucocorticoid synthesis. Moreover, maternal glucocorticoids can potentially cross the placenta. To enable pregnancy and ensure proper fetal development, glucocorticoid signaling occurs during three period of gestation: early in pregnancy to enable implantation, between week 7 and 14 to enable fetal-adrenal development, repress DHEA synthesis and enable female genital development and finally during the third trimester. Fetal serum glucocorticoid levels must increase significantly before birth in order to ensure proper development of the lungs and several other organs. On the other hand, the fetus should not be exposed to excessive levels of glucocorticoids; this can suppress fetal growth and program the fetus for life-long diseases such as hypertension, glucose intolerance, diabetes, and strokes.

80In the adrenal gland, cortisol synthesis is initiated by 21-hydroxylase (CYP21A2). CYP21A2 converts progesterone as well as 17α-OH-progesterone, through a hydroxylation at position C21, into 11-deoxycorticosterone and 11-deoxycortisol, respectively. After catalyzation by CYP21A2, 11β-hydroxylase (CYP11B1), and 11β-HSD are the key molecules mediating and regulating tissue-specific glucocorticoid actions. CYP11B1 catalyzes 11-deoxycorticosterone and 11-deoxycortisol to corticosterone and cortisol, respectively. There has been no evidence so far of CYP21A2 or CYP11B1 expression in human placenta. However, 11β-HSD type 1 and 2 isozymes are expressed in the placenta and the fetal membranes. 11β-HSD2 is an oxidase converting cortisol to the inactive 11-keto metabolite, cortisone. 11β-HSD1, in contrast, preferentially acts as a reductase in vivo, mediating the NADPH-dependent conversion of cortisone to cortisol (Figure 7). In line with this, reported increasing conversion of cortisone to cortisol in homogenized human placental tissue toward term, although conversion from cortisol to inactive cortisone predominated at all gestational ages.

81Cortisol is required during early pregnancy for the establishment of gestation. 11β-HSD1 and GR are localized widely in the decidual stroma and epithelium, while the distribution of 11β-HSD2 is mainly confined to the decidual epithelium and scarcely observed in the decidual stroma. Furthermore, 11β-HSD1 is localized only in the fetal blood vessels in the interstitial core of the villous tissue but not in the extravillous trophoblast, CTB and STB. 11β-HSD2 expression is mainly restricted to the STB. The distribution pattern of 11β-HSD1 suggests that higher concentrations of cortisol are required on the maternal side than on the fetal side in early pregnancy.

82Cortisol levels in the maternal circulation rise toward term. As steroid hormones use free diffusion to enter target cells, maternal cortisol reaches placental cells. Overexposure of the fetus to glucocorticoids during pregnancy reduces birth weight and can be detrimental to fetal development. In the human placenta, 11β-HSD2 acts as a major “barrier” to materno-fetal cortisol transfer as shown in the isolated perfused placenta. 11β-HSD2 is localized abundantly in the STB and generates a cortisone-to-cortisol-ratio >1. CRH and cortisol induce the expression of 11β-HSD2 in isolated trophoblasts. Furthermore, cortisol stimulates hCG production in trophoblasts and the upregulation of 11β-HSD2 expression in trophoblasts by cortisol may be mediated in part by hCG. Nevertheless, the conversion of cortisol is incomplete and a fraction of cortisol remains unmetabolized. The energy-dependent drug-efflux pump ABCB1 may mediate export of glucocorticoids from cells. Studies in BeWo cells suggested that this transporter could contribute to the placental glucocorticoid barrier. ABCB1 is expressed at the apical surface of the STB. In CTBs, the glucocorticoid drugs dexamethasone and betamethasone, significantly induce the expression of ABCB1. 11β-HSD2 and ABCB1 may thus act together to reduce fetal and placental exposure to maternal cortisol and thereby minimize the growth inhibitory action on the fetus (Figure 8).

8311β-HSD1 and 2 are key molecules in the production and metabolism of glucocorticoids. Both are expressed in the human decidua and placenta and both are related to a number of pregnancy-associated complications. 11β-HSD1 is implicated in the pathogenesis of metabolic syndrome. 11β-HSD1 expression is altered in preeclampsia as well as IUGR and gene polymorphisms are associated with hypertensive disorders of pregnancy. Likewise, reduced 11β-HSD2 activity is related to preeclampsia, IUGR, and adverse pregnancy outcome (preterm birth). These interesting studies have been extensively reviewed in a recent publication. Many of the underlying mechanisms causing altered expression of the enzymes remain to be explored, and additionally suspected correlations between altered enzyme expression and diseases such as GDM need to be confirmed. In addition, it remains to be demonstrated whether gene polymorphisms in 11β-HSD2 could serve as biomarkers for hypertensive disorders of pregnancy.

Summary And Outlook

84Cholesterol, progesterone, estrogens, and cortisol are required to establish and maintain pregnancy and ensure healthy fetal development. The human placenta, located at the interface of maternal and fetal circulation, has an active role in biosynthesis, metabolism, and transport of these molecules. Many enzymes and transporters are involved in these processes but our knowledge concerning their function and regulation is incomplete. The placental barrier is composed of trophoblast cells and pFECs. Few studies have addressed the role of pFECs in placental steroid handling. The functional interdependence of trophoblasts, pFECs, and fetal adrenal cells is incompletely understood. The use of co-culture systems may significantly broaden our understanding.

85Diseases, but also external factors such as high fat diet or smoking alter the placental steroid metabolism. We need to explore these alterations and their potential consequences for fetus or mother. It should be kept in mind that the enzymes and transporters involved are regulated at multiple levels and by many endogenous molecules. Thus, whenever possible, mRNA levels, protein levels and posttranslational modifications should be examined. Likewise, when looking for changes in the concentration levels of steroids or other substances, subcellular fractionation should be considered in order not to miss important details. Apart from diseases, we are facing an ever-growing number of toxic substances in the environment. As the steroid metabolism of the human placenta is crucial for life long health of fetus and mother, we should be interested to understand their influence on the function of the human placenta.

Author Contributions

86WC, KJ, and IE designed and wrote the article and met all criteria for authorship.

Conflict of Interest Statement

87The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 370

1.
Acikgoz S. Bayar U. O. Can M. Guven B. Mungan G. Dogan S. (2013 ). Levels of oxidized LDL, estrogens, and progesterone in placenta tissues and serum paraoxonase activity in preeclampsia. Mediators Inflamm. 2013:862982.
Not in our library10.1155/2013/862982
2.
Albrecht C. Soumian S. Tetlow N. Patel P. Sullivan M. H. Lakasing L. (2007 ). Placental ABCA1 expression is reduced in primary antiphospholipid syndrome compared to pre-eclampsia and controls. Placenta 28 701–708.
Not in our library10.1016/j.placenta.2006.10.001
3.
Albrecht E. D. Babischkin J. S. Koos R. D. Pepe G. J. (1995 ). Developmental increase in low density lipoprotein receptor messenger ribonucleic acid levels in placental syncytiotrophoblasts during baboon pregnancy. Endocrinology 136 5540–5546.
Not in our library10.1210/endo.136.12.7588306
4.
Alsat E. Bouali Y. Goldstein S. Malassine A. Berthelier M. Mondon F. (1984 ). Low-density lipoprotein binding sites in the microvillous membranes of human placenta at different stages of gestation. Mol. Cell. Endocrinol. 38 197–203.
Not in our library10.1016/0303-7207(84)90118-7
5.
Alsat E. Bouali Y. Goldstein S. Malassine A. Laudat M. H. Cedard L. (1982 ). Characterization of specific low-density lipoprotein binding sites in human term placental microvillous membranes. Mol. Cell. Endocrinol. 28 439–453.
Not in our library10.1016/0303-7207(82)90138-1
6.
Alsat E. Malassine A. (1991 ). High density lipoprotein interaction with human placenta: biochemical and ultrastructural characterization of binding to microvillous receptor and lack of internalization. Mol. Cell. Endocrinol. 77 97–108.
Not in our library10.1016/0303-7207(91)90063-x
7.
Arabin B. Baschat A. A. (2017 ). Pregnancy: an underutilized window of opportunity to improve long-term maternal and infant health-an appeal for continuous family care and interdisciplinary communication. Front. Pediatr. 5:69.
Not in our library10.3389/fped.2017.00069
8.
Aye I. L. Singh A. T. Keelan J. A. (2009 ). Transport of lipids by ABC proteins: interactions and implications for cellular toxicity, viability and function. Chem. Biol. Interact. 180 327–339.
Not in our library10.1016/j.cbi.2009.04.012
9.
Aye I. L. Waddell B. J. Mark P. J. Keelan J. A. (2010 ). Placental ABCA1 and ABCG1 transporters efflux cholesterol and protect trophoblasts from oxysterol induced toxicity. Biochim. Biophys. Acta 1801 1013–1024.
Not in our library10.1016/j.bbalip.2010.05.015
10.
Aye I. L. Waddell B. J. Mark P. J. Keelan J. A. (2011 ). Oxysterols inhibit differentiation and fusion of term primary trophoblasts by activating liver X receptors. Placenta 32 183–191.
Not in our library10.1016/j.placenta.2010.12.007
11.
Aye I. L. Waddell B. J. Mark P. J. Keelan J. A. (2012 ). Oxysterols exert proinflammatory effects in placental trophoblasts via TLR4-dependent, cholesterol-sensitive activation of NF-kappaB. Mol. Hum. Reprod. 18 341–353.
Not in our library10.1093/molehr/gas001
12.
Baardman M. E. Erwich J. J. Berger R. M. Hofstra R. M. Kerstjens-Frederikse W. S. Lutjohann D. (2012 ). The origin of fetal sterols in second-trimester amniotic fluid: endogenous synthesis or maternal-fetal transport? Am. J. Obstet. Gynecol. 207 202.e19–225.e19.
Not in our library10.1016/j.ajog.2012.06.003
13.
Baardman M. E. Kerstjens-Frederikse W. S. Berger R. M. F. Bakker M. K. Hofstra R. M. W. Plosch T. (2013 ). The role of maternal-fetal cholesterol transport in early fetal life: current insights. Biol. Reprod. 88:24.
Not in our library10.1095/biolreprod.112.102442
14.
Babischkin J. S. Grimes R. W. Pepe G. J. Albrecht E. D. (1997a ). Estrogen stimulation of P450 cholesterol side-chain cleavage activity in cultures of human placental syncytiotrophoblasts. Biol. Reprod. 56 272–278.
Not in our library10.1095/biolreprod56.1.272
15.
Babischkin J. S. Pepe G. J. Albrecht E. D. (1997b ). Estrogen regulation of placental P-450 cholesterol side-chain cleavage enzyme messenger ribonucleic acid levels and activity during baboon pregnancy. Endocrinology 138 452–459.
Not in our library10.1210/endo.138.1.4833
16.
Bahn R. S. Worsham A. Speeg K. V. Jr. Ascoli M. Rabin D. (1981 ). Characterization of steroid production in cultured human choriocarcinoma cells. J. Clin. Endocrinol. Metab. 52 447–450.
Not in our library10.1210/jcem-52-3-447
17.
Baird D. T. Cockburn F. Galbraith A. Kelly R. Livingstone J. R. (1973 ). Formation of progesterone and pregnenolone from (4- 14 C) cholesterol by the intact mid-term human foeto-placental unit perfused in vitro. J. Endocrinol. 56 187–202.
Not in our library10.1677/joe.0.0560187
18.
Bansal N. Cruickshank J. K. McElduff P. Durrington P. N. (2005 ). Cord blood lipoproteins and prenatal influences. Curr. Opin. Lipidol. 16 400–408.
Not in our library10.1097/01.mol.0000174154.61307.16
19.
Barker D. J. Thornburg K. L. (2013 ). Placental programming of chronic diseases, cancer and lifespan: a review. Placenta 34 841–845.
Not in our library10.1016/j.placenta.2013.07.063
20.
Bartel D. P. (2009 ). MicroRNAs: target recognition and regulatory functions. Cell 136 215–233.
Not in our library10.1016/j.cell.2009.01.002
21.
Baumann M. Korner M. Huang X. Wenger F. Surbek D. Albrecht C. (2013 ). Placental ABCA1 and ABCG1 expression in gestational disease: pre-eclampsia affects ABCA1 levels in syncytiotrophoblasts. Placenta 34 1079–1086.
Not in our library10.1016/j.placenta.2013.06.309
22.
Belknap W. M. Dietschy J. M. (1988 ). Sterol synthesis and low density lipoprotein clearance in vivo in the pregnant rat, placenta, and fetus. Sources for tissue cholesterol during fetal development. J. Clin. Invest. 82 2077–2085.
Not in our library10.1172/jci113829
23.
Belo L. Caslake M. Santos-Silva A. Castro E. M. Pereira-Leite L. Quintanilha A. (2004 ). LDL size, total antioxidant status and oxidised LDL in normal human pregnancy: a longitudinal study. Atherosclerosis 177 391–399.
Not in our library10.1016/j.atherosclerosis.2004.07.023
24.
Benirschke K. Burton G. G. J. Baergen R. N. (2012 ). Pathology of the Human Placenta. ed. Benirschke K. Heidelberg: Springer
Not in our library10.1007/978-3-642-23941-0
25.
Bhattacharjee J. Ietta F. Giacomello E. Bechi N. Romagnoli R. Fava A. (2010 ). Expression and localization of ATP binding cassette transporter A1 (ABCA1) in first trimester and term human placenta. Placenta 31 423–430.
Not in our library10.1016/j.placenta.2010.02.015
26.
Bicknell A. B. (2008 ). The tissue-specific processing of pro-opiomelanocortin. J. Neuroendocrinol. 20 692–699.
Not in our library10.1111/j.1365-2826.2008.01709.x
27.
Bilban M. Tauber S. Haslinger P. Pollheimer J. Saleh L. Pehamberger H. (2010 ). Trophoblast invasion: assessment of cellular models using gene expression signatures. Placenta 31 989–996.
Not in our library10.1016/j.placenta.2010.08.011
28.
Bjorkhem I. (2002 ). Do oxysterols control cholesterol homeostasis? J. Clin. Invest. 110 725–730.
Not in our library10.1172/jci16388
29.
Blassberg R. Jacob J. (2017 ). Lipid metabolism fattens up hedgehog signaling. BMC Biol. 15:95.
Not in our library10.1186/s12915-017-0442-y
30.
Bloch K. (1965 ). The biological synthesis of cholesterol. Science 150 19–28.
Not in our library10.1126/science.150.3692.19
31.
Bloise E. Ortiga-Carvalho T. M. Reis F. M. Lye S. J. Gibb W. Matthews S. G. (2016 ). ATP-binding cassette transporters in reproduction: a new frontier. Hum. Reprod. Update 22 164–181.
Not in our library10.1093/humupd/dmv049
32.
Blundell C. Tess E. R. Schanzer A. S. Coutifaris C. Su E. J. Parry S. (2016 ). A microphysiological model of the human placental barrier. Lab Chip 16 3065–3073.
Not in our library10.1039/c6lc00259e
33.
Blundell C. Yi Y. S. Ma L. Tess E. R. Farrell M. J. Georgescu A. (2018 ). Placental drug transport-on-a-chip: a microengineered in vitro model of transporter-mediated drug efflux in the human placental barrier. Adv. Healthc. Mater. 7:1700786.
Not in our library10.1002/adhm.201700786
34.
Bodzek P. Janoszka B. Wielkoszynski T. Bodzek D. Sieron A. (2002a ). Concentration of chosen oxycholesterols in plasma of pregnant women with pregnancy-induced hypertension. Biomed. Chromatogr. 16 13–18.
Not in our library10.1002/bmc.114
35.
Bodzek P. Olejek A. Zamlynski J. (2002b ). [Concentration of the oxygenated derivates of cholesterol in pregnant women suffering from diabetes type I]. Wiad Lek 55(Suppl. 1), 50–53.
Not in our library
36.
Boguslawski W. Sokolowski W. (1984 ). HMG-CoA reductase activity in the microsomal fraction from human placenta in early and term pregnancy. Int. J. Biochem. 16 1023–1026.
Not in our library10.1016/0020-711x(84)90120-4
37.
Bokslag A. van Weissenbruch M. Mol B. W. de Groot C. J. (2016 ). Preeclampsia; short and long-term consequences for mother and neonate. Early Hum. Dev. 102 47–50.
Not in our library10.1016/j.earlhumdev.2016.09.007
38.
Bonenfant M. Provost P. R. Drolet R. Tremblay Y. (2000 ). Localization of type 1 17beta-hydroxysteroid dehydrogenase mRNA and protein in syncytiotrophoblasts and invasive cytotrophoblasts in the human term villi. J. Endocrinol. 165 217–222.
Not in our library10.1677/joe.0.1650217
39.
Bonet B. Brunzell J. D. Gown A. M. Knopp R. H. (1992 ). Metabolism of very-low-density lipoprotein triglyceride by human placental cells: the role of lipoprotein lipase. Metabolism 41 596–603.
Not in our library10.1016/0026-0495(92)90051-b
40.
Bose H. S. Whittal R. M. Huang M. C. Baldwin M. A. Miller W. L. (2000 ). N-218 MLN64, a protein with StAR-like steroidogenic activity, is folded and cleaved similarly to StAR. Biochemistry 39 11722–11731.
Not in our library10.1021/bi000911l
41.
Bose P. D. Das B. C. Kumar A. Gondal R. Kumar D. Kar P. (2011 ). High viral load and deregulation of the progesterone receptor signaling pathway: association with hepatitis E-related poor pregnancy outcome. J. Hepatol. 54 1107–1113.
Not in our library10.1016/j.jhep.2010.08.037
42.
Maternal–Fetal Nutrient Transport in Pregnancy Pathologies: The Role of the Placenta · 2014
No notice
43.
Brownfoot F. C. Hannan N. Onda K. Tong S. Kaitu’u-Lino T. (2014 ). Soluble endoglin production is upregulated by oxysterols but not quenched by pravastatin in primary placental and endothelial cells. Placenta 35 724–731.
Not in our library10.1016/j.placenta.2014.06.374
44.
Burke K. A. Jauniaux E. Burton G. J. Cindrova-Davies T. (2013 ). Expression and immunolocalisation of the endocytic receptors megalin and cubilin in the human yolk sac and placenta across gestation. Placenta 34 1105–1109.
Not in our library10.1016/j.placenta.2013.08.003
45.
Burke K. T. Colvin P. L. Myatt L. Graf G. A. Schroeder F. Woollett L. A. (2009 ). Transport of maternal cholesterol to the fetus is affected by maternal plasma cholesterol concentrations in the golden Syrian hamster. J. Lipid Res. 50 1146–1155.
Not in our library10.1194/jlr.m800538-jlr200
46.
Burton G. J. Charnock-Jones D. S. Jauniaux E. (2009 ). Regulation of vascular growth and function in the human placenta. Reproduction 138 895–902.
Not in our library10.1530/rep-09-0092
47.
Burton G. J. Fowden A. L. Thornburg K. L. (2016 ). Placental origins of Chronic disease. Physiol. Rev. 96 1509–1565.
Not in our library10.1152/physrev.00029.2015
48.
Burton G. J. Hempstock J. Jauniaux E. (2001 ). Nutrition of the human fetus during the first trimester–a review. Placenta 22(Suppl. A), S70–S77.
Not in our library10.1053/plac.2001.0639
49.
Busada J. T. Cidlowski J. A. (2017 ). Mechanisms of glucocorticoid action during development. Curr. Top. Dev. Biol. 125 147–170.
Not in our library10.1016/bs.ctdb.2016.12.004
50.
Bussen S. Bussen D. (2011 ). Influence of the vascular endothelial growth factor on the development of severe pre-eclampsia or HELLP syndrome. Arch. Gynecol. Obstet. 284 551–557.
Not in our library10.1007/s00404-010-1704-x
51.
Cao C. Pressman E. K. Cooper E. M. Guillet R. Westerman M. O’Brien K. O. (2014 ). Placental heme receptor LRP1 correlates with the heme exporter FLVCR1 and neonatal iron status. Reproduction 148 295–302.
Not in our library10.1530/rep-14-0053
52.
Cao G. Garcia C. K. Wyne K. L. Schultz R. A. Parker K. L. Hobbs H. H. (1997 ). Structure and localization of the human gene encoding SR-BI/CLA-1. Evidence for transcriptional control by steroidogenic factor 1. J. Biol. Chem. 272 33068–33076.
Not in our library10.1074/jbc.272.52.33068
53.
Cao S. Ye L. Wu Y. Mao B. Chen L. Wang X. (2017 ). The effects of fungicides on human 3beta-Hydroxysteroid Dehydrogenase 1 and aromatase in human placental cell line JEG-3. Pharmacology 100 139–147.
Not in our library10.1159/000475531
54.
Cardoso R. C. Puttabyatappa M. Padmanabhan V. (2015 ). Steroidogenic versus metabolic programming of reproductive neuroendocrine, ovarian and metabolic dysfunctions. Neuroendocrinology 102 226–237.
Not in our library10.1159/000381830
55.
Carter A. M. (2007 ). Animal models of human placentation–a review. Placenta 28(Suppl. A), S41–S47.
Not in our library10.1016/j.placenta.2006.11.002
56.
Carter A. M. Enders A. C. (2016 ). Placentation in mammals: definitive placenta, yolk sac, and paraplacenta. Theriogenology 86 278–287.
Not in our library10.1016/j.theriogenology.2016.04.041
57.
Castro M. Elias L. L. Elias P. C. L. Moreira A. C. (2011 ). “Physiology and pathophysiology of the HPA Axis,” in Cushing’s Syndrome: Pathophysiology, Diagnosis and Treatment, ed. Bronstein M. D. (Totowa, NJ: Humana Press), 1–20.
Not in our library
58.
Catov J. M. Bodnar L. M. Kip K. E. Hubel C. Ness R. B. Harger G. (2007 ). Early pregnancy lipid concentrations and spontaneous preterm birth. Am. J. Obstet. Gynecol. 197 610.e1–617.e1.
Not in our library10.1016/j.ajog.2007.04.024
59.
Cavender C. P. Turley S. D. Dietschy J. M. (1995 ). Sterol metabolism in fetal, newborn, and suckled lambs and their response to cholesterol after weaning. Am. J. Physiol. 269 E331–E340.
Not in our library10.1152/ajpendo.1995.269.2.e331
60.
Cerqueira N. M. Oliveira E. F. Gesto D. S. Santos-Martins D. Moreira C. Moorthy H. N. (2016 ). Cholesterol biosynthesis: a mechanistic overview. Biochemistry 55 5483–5506.
Not in our library10.1021/acs.biochem.6b00342
61.
Cha S. H. Sekine T. Kusuhara H. Yu E. Kim J. Y. Kim D. K. (2000 ). Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J. Biol. Chem. 275 4507–4512.
Not in our library10.1074/jbc.275.6.4507
62.
Challis J. R. Matthews S. G. Van Meir C. Ramirez M. M. (1995 ). Current topic: the placental corticotrophin-releasing hormone-adrenocorticotrophin axis. Placenta 16 481–502.
Not in our library10.1016/s0143-4004(05)80001-3
63.
Chigusa Y. Kondoh E. Mogami H. Nishimura F. Ujita M. Kawasaki K. (2013 ). ATP-binding cassette transporter A1 expression is decreased in preeclamptic placentas. Reprod. Sci. 20 891–898.
Not in our library10.1177/1933719112468956
64.
Collier A. C. Miyagi S. J. Yamauchi Y. Ward M. A. (2009 ). Assisted reproduction technologies impair placental steroid metabolism. J. Steroid Biochem. Mol. Biol. 116 21–28.
Not in our library10.1016/j.jsbmb.2009.04.005
65.
Connor W. E. Lin D. S. (1967 ). Placental transfer of cholesterol-4-14C into rabbit and guinea pig fetus. J. Lipid Res. 8 558–564.
Not in our library
66.
Costa M. A. (2016 ). The endocrine function of human placenta: an overview. Reprod. Biomed. Online 32 14–43.
Not in our library10.1016/j.rbmo.2015.10.005
67.
Coukos G. Gafvels M. E. Wittmaack F. Matsuo H. Strickland D. K. Coutifaris C. (1994 ). Potential roles for the low-density-lipoprotein receptor family of proteins in implantation and placentation. Ann. N. Y. Acad. Sci. 734 91–102.
Not in our library10.1111/j.1749-6632.1994.tb21738.x
68.
Cox B. Leavey K. Nosi U. Wong F. Kingdom J. (2015 ). Placental transcriptome in development and pathology: expression, function, and methods of analysis. Am. J. Obstet. Gynecol. 213 S138–S151.
Not in our library10.1016/j.ajog.2015.07.046
69.
Cvitic S. Longtine M. S. Hackl H. Wagner K. Nelson M. D. Desoye G. (2013 ). The human placental sexome differs between trophoblast epithelium and villous vessel endothelium. PLoS One 8:e79233.
Not in our library10.1371/journal.pone.0079233
70.
Desforges M. Sibley C. P. (2010 ). Placental nutrient supply and fetal growth. Int. J. Dev. Biol. 54 377–390.
Not in our library10.1387/ijdb.082765md
71.
Di Renzo G. C. Giardina I. Clerici G. Brillo E. Gerli S. (2016 ). Progesterone in normal and pathological pregnancy. Horm. Mol. Biol. Clin. Investig. 27 35–48.
Not in our library10.1515/hmbci-2016-0038
72.
Di Renzo G. C. Giardina I. Clerici G. Mattei A. Alajmi A. H. Gerli S. (2012 ). The role of progesterone in maternal and fetal medicine. Gynecol. Endocrinol. 28 925–932.
Not in our library10.3109/09513590.2012.730576
73.
Drolet R. Simard M. Plante J. Laberge P. Tremblay Y. (2007 ). Human type 2 17 beta-hydroxysteroid dehydrogenase mRNA and protein distribution in placental villi at mid and term pregnancy. Reprod. Biol. Endocrinol. 5:30.
Not in our library10.1186/1477-7827-5-30
74.
Drwal E. Rak A. Gregoraszczuk E. (2018 ). Co-culture of JEG-3, BeWo and syncBeWo cell lines with adrenal H295R cell line: an alternative model for examining endocrine and metabolic properties of the fetoplacental unit. Cytotechnology 70 285–297.
Not in our library10.1007/s10616-017-0142-z
75.
Dube E. Ethier-Chiasson M. Lafond J. (2013 ). Modulation of cholesterol transport by insulin-treated gestational diabetes mellitus in human full-term placenta. Biol. Reprod. 88:16.
Not in our library10.1095/biolreprod.112.105619
76.
Duttaroy A. K. Basak S. (2015 ). Human Placental Trophoblasts: Impact of Maternal Nutrition. Boca Raton, FL: CRC Press
Not in our library10.1201/b19151
77.
Eades C. E. Cameron D. M. Evans J. M. M. (2017 ). Prevalence of gestational diabetes mellitus in Europe: a meta-analysis. Diabetes Res. Clin. Pract. 129 173–181.
Not in our library10.1016/j.diabres.2017.03.030
78.
Edison R. J. Berg K. Remaley A. Kelley R. Rotimi C. Stevenson R. E. (2007 ). Adverse birth outcome among mothers with low serum cholesterol. Pediatrics 120 723–733.
Not in our library10.1542/peds.2006-1939
79.
Elustondo P. Martin L. A. Karten B. (2017 ). Mitochondrial cholesterol import. Biochim. Biophys. Acta 1862 90–101.
Not in our library10.1016/j.bbalip.2016.08.012
80.
Enquobahrie D. A. Meller M. Rice K. Psaty B. M. Siscovick D. S. Williams M. A. (2008 ). Differential placental gene expression in preeclampsia. Am. J. Obstet. Gynecol. 199 566.e561–511.e11.
Not in our library10.1016/j.ajog.2008.04.020
81.
Ermini L. Post M. Caniggia I. (2017 ). Statins, mevalonate pathway and its intermediate products in placental development and preeclampsia. Curr. Mol. Pharmacol. 10 152–160.
Not in our library10.2174/1874467209666160112123457
82.
Escobar J. C. Carr B. R. (2011 ). The protein kinase a pathway regulates CYP17 expression and androgen production in the human placenta. J. Clin. Endocrinol. Metab. 96 2869–2873.
Not in our library10.1210/jc.2011-0542
83.
Escobar J. C. Patel S. S. Beshay V. E. Suzuki T. Carr B. R. (2011 ). The human placenta expresses CYP17 and generates androgens de novo. J. Clin. Endocrinol. Metab. 96 1385–1392.
Not in our library10.1210/jc.2010-2504
84.
Esparza-Perusquia M. Olvera-Sanchez S. Flores-Herrera O. Flores-Herrera H. Guevara-Flores A. Pardo J. P. (2015 ). Mitochondrial proteases act on STARD3 to activate progesterone synthesis in human syncytiotrophoblast. Biochim. Biophys. Acta 1850 107–117.
Not in our library10.1016/j.bbagen.2014.10.009
85.
Esteve-Valverde E. Ferrer-Oliveras R. Gil-Aliberas N. Baraldes-Farre A. Llurba E. Alijotas-Reig J. (2018 ). Pravastatin for preventing and treating preeclampsia: a systematic review. Obstet. Gynecol. Surv. 73 40–55.
Not in our library10.1097/ogx.0000000000000522
86.
Ethier-Chiasson M. Duchesne A. Forest J. C. Giguere Y. Masse A. Mounier C. (2007 ). Influence of maternal lipid profile on placental protein expression of LDLr and SR-BI. Biochem. Biophys. Res. Commun. 359 8–14.
Not in our library10.1016/j.bbrc.2007.05.002
87.
Evain-Brion D. Malassine A. (2003 ). Human placenta as an endocrine organ. Growth Horm. IGF Res. 13(Suppl. A), S34–S37.
Not in our library10.1016/s1096-6374(03)00053-4
88.
Fahlbusch F. B. Ruebner M. Volkert G. Offergeld R. Hartner A. Menendez-Castro C. (2012 ). Corticotropin-releasing hormone stimulates expression of leptin, 11beta-HSD2 and syncytin-1 in primary human trophoblasts. Reprod. Biol. Endocrinol. 10:80.
Not in our library10.1186/1477-7827-10-80
89.
Favari E. Chroni A. Tietge U. J. Zanotti I. Escola-Gil J. C. Bernini F. (2015 ). Cholesterol efflux and reverse cholesterol transport. Handb. Exp. Pharmacol. 224 181–206.
Not in our library10.1007/978-3-319-09665-0_4
90.
Florio P. Franchini A. Reis F. M. Pezzani I. Ottaviani E. Petraglia F. (2000 ). Human placenta, chorion, amnion and decidua express different variants of corticotropin-releasing factor receptor messenger RNA. Placenta 21 32–37.
Not in our library10.1053/plac.1999.0461
91.
Forbes K. Hurst L. M. Aplin J. D. Westwood M. Gibson J. M. (2008 ). Statins are detrimental to human placental development and function; use of statins during early pregnancy is inadvisable. J. Cell Mol. Med. 12 2295–2296.
Not in our library10.1111/j.1582-4934.2008.00466.x
92.
Forbes K. Shah V. K. Siddals K. Gibson J. M. Aplin J. D. Westwood M. (2015 ). Statins inhibit insulin-like growth factor action in first trimester placenta by altering insulin-like growth factor 1 receptor glycosylation. Mol. Hum. Reprod. 21 105–114.
Not in our library10.1093/molehr/gau093
93.
Fournier T. Handschuh K. Tsatsaris V. Guibourdenche J. Evain-Brion D. (2008 ). Role of nuclear receptors and their ligands in human trophoblast invasion. J. Reprod. Immunol. 77 161–170.
Not in our library10.1016/j.jri.2007.05.004
94.
Fowden A. L. Forhead A. J. Sferruzzi-Perri A. N. Burton G. J. Vaughan O. R. (2015 ). Review: endocrine regulation of placental phenotype. Placenta 36(Suppl. 1), S50–S59.
Not in our library10.1016/j.placenta.2014.11.018
95.
French A. P. Warren J. C. (1965 ). Steroid-3-beta-sulfatase in fetal and placental tissues. Steroids 6 865–869.
Not in our library10.1016/0039-128x(65)90107-8
96.
Frim D. M. Robinson B. G. Pasieka K. B. Majzoub J. A. (1990 ). Differential regulation of corticotropin-releasing hormone mRNA in rat brain. Am. J. Physiol. 258(4 Pt 1), E686–E692.
Not in our library10.1152/ajpendo.1990.258.4.e686
97.
Fukata Y. Yu X. Imachi H. Nishiuchi T. Lyu J. Seo K. (2014 ). 17beta-Estradiol regulates scavenger receptor class BI gene expression via protein kinase C in vascular endothelial cells. Endocrine 46 644–650.
Not in our library10.1007/s12020-013-0134-5
98.
Furuhashi M. Seo H. Mizutani S. Narita O. Tomoda Y. Matsui N. (1989 ). Expression of low density lipoprotein receptor gene in human placenta during pregnancy. Mol. Endocrinol. 3 1252–1256.
Not in our library10.1210/mend-3-8-1252
99.
Gafvels M. E. Caird M. Britt D. Jackson C. L. Patterson D. Strauss J. F. III (1993 ). Cloning of a cDNA encoding a putative human very low density lipoprotein/apolipoprotein E receptor and assignment of the gene to chromosome 9pter-p23. Somat. Cell Mol. Genet. 19 557–569.
Not in our library10.1007/bf01233382
100.
Gafvels M. E. Coukos G. Sayegh R. Coutifaris C. Strickland D. K. Strauss J. F. III (1992 ). Regulated expression of the trophoblast alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Differentiation and cAMP modulate protein and mRNA levels. J. Biol. Chem. 267 21230–21234.
Not in our library
101.
Gallo L. A. Barrett H. L. Dekker Nitert M. (2016 ). Review: placental transport and metabolism of energy substrates in maternal obesity and diabetes. Placenta 54 59–67
Not in our library10.1016/j.placenta.2016.12.006
102.
Gangestad S. W. Caldwell Hooper A. E. Eaton M. A. (2012 ). On the function of placental corticotropin-releasing hormone: a role in maternal-fetal conflicts over blood glucose concentrations. Biol. Rev. Camb. Philos. Soc. 87 856–873.
Not in our library10.1111/j.1469-185x.2012.00226.x
103.
Gao L. Lu C. Xu C. Tao Y. Cong B. Ni X. (2008 ). Differential regulation of prostaglandin production mediated by corticotropin-releasing hormone receptor type 1 and type 2 in cultured human placental trophoblasts. Endocrinology 149 2866–2876.
Not in our library10.1210/en.2007-1377
104.
Gao L. Lv C. Xu C. Li Y. Cui X. Gu H. (2012 ). Differential regulation of glucose transporters mediated by CRH receptor type 1 and type 2 in human placental trophoblasts. Endocrinology 153(3), g1464–1471.
Not in our library10.1210/en.2011-1673
105.
Geyer J. Bakhaus K. Bernhardt R. Blaschka C. Dezhkam Y. Fietz D. (2017 ). The role of sulfated steroid hormones in reproductive processes. J. Steroid Biochem. Mol. Biol. 172 207–221.
Not in our library10.1016/j.jsbmb.2016.07.002
106.
Ghorashi V. Sheikhvatan M. (2008 ). The relationship between serum concentration of free testosterone and pre-eclampsia. Endokrynol. Pol. 59 390–392.
Not in our library
107.
Giannopoulos G. Jackson K. Tulchinsky D. (1982 ). Glucocorticoid metabolism in human placenta, decidua, myometrium and fetal membranes. J. Steroid Biochem. 17 371–374.
Not in our library10.1016/0022-4731(82)90628-8
108.
Go G. W. Mani A. (2012 ). Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J. Biol. Med. 85 19–28.
Not in our library
109.
Gohner C. Svensson-Arvelund J. Pfarrer C. Hager J. D. Faas M. Ernerudh J. (2014 ). The placenta in toxicology. Part IV: battery of toxicological test systems based on human placenta. Toxicol. Pathol. 42 345–351.
Not in our library10.1177/0192623313482206
110.
Goldkrand J. W. Schulte R. L. Messer R. H. (1976 ). Maternal and fetal plasma cortisol levels at parturition. Obstet. Gynecol. 47 41–45.
Not in our library
111.
Goodarzi M. O. Dumesic D. A. Chazenbalk G. Azziz R. (2011 ). Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat. Rev. Endocrinol. 7:219.
Not in our library10.1038/nrendo.2010.217
112.
Grammatopoulos D. K. Ourailidou S. (2017 ). CRH receptor signalling: potential roles in pathophysiology. Curr. Mol. Pharmacol. 10 296–310.
Not in our library10.2174/1874467210666170110125747
113.
Gratton A. M. Ye L. Brownfoot F. C. Hannan N. J. Whitehead C. Cannon P. (2016 ). Steroid sulfatase is increased in the placentas and whole blood of women with early-onset preeclampsia. Placenta 48(Suppl. C), 72–79.
Not in our library10.1016/j.placenta.2016.10.008
114.
Grigsby P. L. (2016 ). Animal models to study placental development and function throughout normal and dysfunctional human pregnancy. Semin. Reprod. Med. 34 11–16.
Not in our library10.1055/s-0035-1570031
115.
Grimes R. W. Pepe G. J. Albrecht E. D. (1996 ). Regulation of human placental trophoblast low-density lipoprotein uptake in vitro by estrogen. J. Clin. Endocrinol. Metab. 81 2675–2679.
Not in our library10.1210/jcem.81.7.8675596
116.
Grube M. Kock K. Karner S. Reuther S. Ritter C. A. Jedlitschky G. (2006 ). Modification of OATP2B1-mediated transport by steroid hormones. Mol. Pharmacol. 70 1735–1741.
Not in our library10.1124/mol.106.026450
117.
Grube M. Reuther S. Meyer Zu Schwabedissen H. Kock K. Draber K. Ritter C. A. (2007 ). Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta. Drug Metab. Dispos. 35 30–35.
Not in our library10.1124/dmd.106.011411
118.
Hafez S. (2017 ). Comparative placental anatomy: divergent structures serving a common purpose. Prog. Mol. Biol. Transl. Sci. 145 1–28.
Not in our library10.1016/bs.pmbts.2016.12.001
119.
Hahnova-Cygalova L. Ceckova M. Staud F. (2011 ). Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy. Drug Metab. Rev. 43 53–68.
Not in our library10.3109/03602532.2010.512293
120.
Hakkola J. Raunio H. Purkunen R. Pelkonen O. Saarikoski S. Cresteil T. (1996 ). Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem. Pharmacol. 52 379–383.
Not in our library10.1016/0006-2952(96)00216-x
121.
Halasz M. Szekeres-Bartho J. (2013 ). The role of progesterone in implantation and trophoblast invasion. J. Reprod. Immunol. 97 43–50.
Not in our library10.1016/j.jri.2012.10.011
122.
Hanukoglu I. (1992 ). Steroidogenic enzymes: structure, function, and role in regulation of steroid hormone biosynthesis. J. Steroid Biochem. Mol. Biol. 43 779–804.
Not in our library10.1016/0960-0760(92)90307-5
123.
He D. Meloche C. A. Dumas N. A. Frost A. R. Falany C. N. (2004 ). Different subcellular localization of sulphotransferase 2B1b in human placenta and prostate. Biochem. J. 379(Pt 3), 533–540.
Not in our library10.1042/bj20031524
124.
He G. Xu W. Chen Y. Liu X. Xi M. (2013 ). Abnormal apoptosis of trophoblastic cells is related to the up-regulation of CYP11A gene in placenta of preeclampsia patients. PLoS One 8:e59609.
Not in our library10.1371/journal.pone.0059609
125.
Hellig H. Gattereau D. Lefebvre Y. Bolte E. (1970 ). Steroid production from plasma cholesterol. I. Conversion of plasma cholesterol to placental progesterone in humans. J. Clin. Endocrinol. Metab. 30 624–631.
Not in our library10.1210/jcem-30-5-624
126.
Henderson Y. C. Frederick M. J. Wang M. T. Hollier L. M. Clayman G. L. (2008 ). LBP-1b, LBP-9, and LBP-32/MGR detected in syncytiotrophoblasts from first-trimester human placental tissue and their transcriptional regulation. DNA Cell Biol. 27 71–79.
Not in our library10.1089/dna.2007.0640
127.
Henson M. C. (1998 ). Pregnancy maintenance and the regulation of placental progesterone biosynthesis in the baboon. Hum. Reprod. Update 4 389–405.
Not in our library10.1093/humupd/4.4.389
128.
Henson M. C. Greene S. J. Reggio B. C. Shi W. Swan K. F. (1997 ). Effects of reduced maternal lipoprotein-cholesterol availability on placental progesterone biosynthesis in the baboon. Endocrinology 138 1385–1391.
Not in our library10.1210/endo.138.4.5039
129.
Henson M. C. Pepe G. J. Albrecht E. D. (1991 ). Regulation of placental low-density lipoprotein uptake in baboons by estrogen: dose-dependent effects of the anti-estrogen ethamoxytriphetol (MER-25). Biol. Reprod. 45 43–48.
Not in our library10.1095/biolreprod45.1.43
130.
Hentschke M. R. Poli-de-Figueiredo C. E. da Costa B. E. Kurlak L. O. Williams P. J. Mistry H. D. (2013 ). Is the atherosclerotic phenotype of preeclamptic placentas due to altered lipoprotein concentrations and placental lipoprotein receptors? Role of a small-for-gestational-age phenotype. J. Lipid Res. 54 2658–2664.
Not in our library10.1194/jlr.m036699
131.
Herman B. E. Szabó J. Bacsa I. Wölfling J. Schneider G. Bálint M. (2016 ). Comparative investigation of the in vitro inhibitory potencies of 13-epimeric estrones and D-secoestrones towards 17β-hydroxysteroid dehydrogenase type 1. J. Enzyme Inhib. Med. Chem. 31(Suppl. 3), 61–69.
Not in our library10.1080/14756366.2016.1204610
132.
Herrera E. (2002 ). Lipid metabolism in pregnancy and its consequences in the fetus and newborn. Endocrine 19 43–55.
Not in our library10.1385/endo:19:1:43
133.
Herrera E. Amusquivar E. Lopez-Soldado I. Ortega H. (2006 ). Maternal lipid metabolism and placental lipid transfer. Horm. Res. 65(Suppl. 3), 59–64.
Not in our library10.1159/000091507
134.
Hertig A. Liere P. Chabbert-Buffet N. Fort J. Pianos A. Eychenne B. (2010 ). Steroid profiling in preeclamptic women: evidence for aromatase deficiency. Am. J. Obstet. Gynecol. 203 477.e1–479.e1.
Not in our library10.1016/j.ajog.2010.06.011
135.
Heussner K. Ruebner M. Huebner H. Rascher W. Menendez-Castro C. Hartner A. (2016 ). Species differences of 11beta-hydroxysteroid dehydrogenase type 2 function in human and rat term placenta determined via LC-MS/MS. Placenta 37 79–84.
Not in our library10.1016/j.placenta.2015.11.009
136.
Hochberg R. B. Vander Hoeven T. A. Welch M. Lieberman S. (1974 ). Simple and precise assay of the enzymic conversion of cholesterol into pregnenolone. Biochemistry 13 603–609.
Not in our library10.1021/bi00700a031
137.
Hu Y. Li P. Hao S. Liu L. Zhao J. Hou Y. (2009 ). Differential expression of microRNAs in the placentae of Chinese patients with severe pre-eclampsia. Clin. Chem. Lab. Med. 47 923–929.
Not in our library10.1515/cclm.2009.228
138.
Huang X. Anderle P. Hostettler L. Baumann M. U. Surbek D. V. Ontsouka E. C. (2018 ). Identification of placental nutrient transporters associated with intrauterine growth restriction and pre-eclampsia. BMC Genomics 19:173.
Not in our library10.1186/s12864-018-4518-z
139.
Hudon Thibeault A. A. Laurent L. Vo Duy S. Sauve S. Caron P. Guillemette C. (2017 ). Fluoxetine and its active metabolite norfluoxetine disrupt estrogen synthesis in a co-culture model of the feto-placental unit. Mol. Cell. Endocrinol. 442 32–39.
Not in our library10.1016/j.mce.2016.11.021
140.
Hudon Thibeault A. A. Vaillancourt C. Sanderson J. T. (2018 ). Profile of CYP19A1 mRNA expression and aromatase activity during syncytialization of primary human villous trophoblast cells at term. Biochimie 148 12–17.
Not in our library10.1016/j.biochi.2018.02.010
141.
Huynh J. Dawson D. Roberts D. Bentley-Lewis R. (2015 ). A systematic review of placental pathology in maternal diabetes mellitus. Placenta 36 101–114.
Not in our library10.1016/j.placenta.2014.11.021
142.
Ian Mason J. (1993 ). The 3beta-hydroxysteroid dehydrogenase gene family of enzymes. Trends Endocrinol. Metab. 4 199–203.
Not in our library10.1016/1043-2760(93)90117-w
143.
Ikonen E. (2006 ). Mechanisms for cellular cholesterol transport: defects and human disease. Physiol. Rev. 86 1237–1261.
Not in our library10.1152/physrev.00022.2005
144.
Ishibashi O. Ohkuchi A. Ali M. M. Kurashina R. Luo S. S. Ishikawa T. (2012 ). Hydroxysteroid (17-beta) dehydrogenase 1 is dysregulated by miR-210 and miR-518c that are aberrantly expressed in preeclamptic placentas: a novel marker for predicting preeclampsia. Hypertension 59 265–273.
Not in our library10.1161/hypertensionaha.111.180232
145.
Jeschke U. Mylonas I. Richter D. U. Hocker I. Briese V. Makrigiannakis A. (2005 ). Regulation of progesterone production in human term trophoblasts in vitro by CRH, ACTH and cortisol (prednisolone). Arch. Gynecol. Obstet. 272 7–12.
Not in our library10.1007/s00404-005-0728-0
146.
Jetten A. M. Takeda Y. Slominski A. Kang H. S. (2018 ). Retinoic acid-related Orphan Receptor gamma (RORgamma): connecting sterol metabolism to regulation of the immune system and autoimmune disease. Curr. Opin. Toxicol. 8 66–80.
Not in our library10.1016/j.cotox.2018.01.005
147.
Jira P. (2013 ). Cholesterol metabolism deficiency. Handb. Clin. Neurol. 113 1845–1850.
Not in our library10.1016/b978-0-444-59565-2.00054-x
148.
Jolibois L. S. Jr. Burow M. E. Swan K. F. George W. J. Anderson M. B. Henson M. C. (1999 ). Effects of cadmium cell viability, trophoblastic development, and expression of low density lipoprotein receptor transcripts in cultured human placental cells. Reprod. Toxicol. 13 473–480.
Not in our library10.1016/s0890-6238(99)00041-6
149.
Jones C. J. Fox H. (1991 ). Ultrastructure of the normal human placenta. Electron. Microsc. Rev. 4 129–178.
Not in our library10.1016/0892-0354(91)90019-9
150.
Jones C. J. Harris L. K. Whittingham J. Aplin J. D. Mayhew T. M. (2008 ). A re-appraisal of the morphophenotype and basal lamina coverage of cytotrophoblasts in human term placenta. Placenta 29 215–219.
Not in our library10.1016/j.placenta.2007.11.004
151.
Jones S. A. Brooks A. N. Challis J. R. (1989 ). Steroids modulate corticotropin-releasing hormone production in human fetal membranes and placenta. J. Clin. Endocrinol. Metab. 68 825–830.
Not in our library10.1210/jcem-68-4-825
152.
Joshi A. A. Vaidya S. S. St-Pierre M. V. Mikheev A. M. Desino K. E. Nyandege A. N. (2016 ). Placental ABC transporters: biological impact and pharmaceutical significance. Pharm. Res. 33 2847–2878.
Not in our library10.1007/s11095-016-2028-8
153.
Jurevics H. A. Kidwai F. Z. Morell P. (1997 ). Sources of cholesterol during development of the rat fetus and fetal organs. J. Lipid Res. 38 723–733.
Not in our library
154.
Kallen C. B. (2004 ). Steroid hormone synthesis in pregnancy. Obstet. Gynecol. Clin. N. Am. 31 795–816.
Not in our library10.1016/j.ogc.2004.08.009
155.
Kamper M. Mittermayer F. Cabuk R. Gelles K. Ellinger I. Hermann M. (2017 ). Estrogen-enhanced apical and basolateral secretion of apolipoprotein B-100 by polarized trophoblast-derived BeWo cells. Biochimie 138 116–123.
Not in our library10.1016/j.biochi.2017.05.006
156.
Kandutsch A. A. Russell A. E. (1960 ). Preputial gland tumor sterols. 3. A metabolic pathway from lanosterol to cholesterol. J. Biol. Chem. 235 2256–2261.
Not in our library
157.
Kang J. S. Choi J. S. Park J. W. (2016 ). Transcriptional changes in steroidogenesis by perfluoroalkyl acids (PFOA and PFOS) regulate the synthesis of sex hormones in H295R cells. Chemosphere 155 436–443.
Not in our library10.1016/j.chemosphere.2016.04.070
158.
Kantarci S. Al-Gazali L. Hill R. S. Donnai D. Black G. C. Bieth E. (2007 ). Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nat. Genet. 39 957–959.
Not in our library10.1038/ng2063
159.
Kanungo S. Soares N. He M. Steiner R. D. (2013 ). Sterol metabolism disorders and neurodevelopment-an update. Dev. Disabil. Res. Rev. 17 197–210.
Not in our library10.1002/ddrr.1114
160.
Karalis K. Goodwin G. Majzoub J. A. (1996 ). Cortisol blockade of progesterone: a possible molecular mechanism involved in the initiation of human labor. Nat. Med. 2 556–560.
Not in our library10.1038/nm0596-556
161.
Kawai M. Swan K. F. Green A. E. Edwards D. E. Anderson M. B. Henson M. C. (2002 ). Placental endocrine disruption induced by cadmium: effects on P450 cholesterol side-chain cleavage and 3beta-hydroxysteroid dehydrogenase enzymes in cultured human trophoblasts. Biol. Reprod. 67 178–183.
Not in our library10.1095/biolreprod67.1.178
162.
Keelan J. A. Aye I. L. Mark P. J. Waddell B. J. (2011 ). ABCA1 and placental cholesterol efflux. Placenta 32 708–709.
Not in our library10.1016/j.placenta.2011.06.004
163.
Kenis I. Tartakover-Matalon S. Cherepnin N. Drucker L. Fishman A. Pomeranz M. (2005 ). Simvastatin has deleterious effects on human first trimester placental explants. Hum. Reprod. 20 2866–2872.
Not in our library10.1093/humrep/dei120
164.
Khamsi F. Merkatz I. Solomon S. (1972 ). The conversion of acetate to cholesterol in the fetus of the baboon and the transfer of cholesterol from mother to fetus. Endocrinology 91 6–12.
Not in our library10.1210/endo-91-1-6
165.
Kim D. H. Iijima H. Goto K. Sakai J. Ishii H. Kim H. J. (1996 ). Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J. Biol. Chem. 271 8373–8380.
Not in our library10.1074/jbc.271.14.8373
166.
Kim Y. J. Park H. Lee H. Y. Ahn Y. M. Ha E. H. Suh S. H. (2007 ). Paraoxonase gene polymorphism, serum lipid, and oxidized low-density lipoprotein in preeclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 133 47–52.
Not in our library10.1016/j.ejogrb.2006.07.046
167.
Kingdom J. Huppertz B. Seaward G. Kaufmann P. (2000 ). Development of the placental villous tree and its consequences for fetal growth. Eur. J. Obstet. Gynecol. Reprod. Biol. 92 35–43.
Not in our library10.1016/s0301-2115(00)00423-1
168.
Knazicka Z. Forgacs Z. Lukacova J. Roychoudhury S. Massanyi P. Lukac N. (2015 ). Endocrine disruptive effects of cadmium on steroidogenesis: human adrenocortical carcinoma cell line NCI-H295R as a cellular model for reproductive toxicity testing. J. Environ. Sci. Health A Tox. Hazard. Subst. Environ. Eng. 50 348–356.
Not in our library10.1080/10934529.2015.987520
169.
Knopp R. H. Montes A. Childs M. Li J. R. Mabuchi H. (1981 ). Metabolic adjustments in normal and diabetic pregnancy. Clin. Obstet. Gynecol. 24 21–49.
Not in our library10.1097/00003081-198103000-00006
170.
Konstantakou P. Mastorakos G. Vrachnis N. Tomlinson J. W. Valsamakis G. (2017 ). Dysregulation of 11beta-hydroxysteroid dehydrogenases: implications during pregnancy and beyond. J. Matern. Fetal Neonatal Med. 30 284–293.
Not in our library10.3109/14767058.2016.1171308
171.
Korber M. Klein I. Daum G. (2017 ). Steryl ester synthesis, storage and hydrolysis: a contribution to sterol homeostasis. Biochim. Biophys. Acta 1862 1534–1545.
Not in our library10.1016/j.bbalip.2017.09.002
172.
Korner M. Wenger F. Nikitina L. Baumann M. Surbek D. Albrecht C. (2012 ). PP141. The lipid transporters ABCA1 and ABCG1 are differentially expressed in preeclamptic and IUGR placentas. Pregnancy Hypertens. 2 315–316.
Not in our library10.1016/j.preghy.2012.04.252
173.
Koutmani Y. Politis P. K. Elkouris M. Agrogiannis G. Kemerli M. Patsouris E. (2013 ). Corticotropin-releasing hormone exerts direct effects on neuronal progenitor cells: implications for neuroprotection. Mol. Psychiatry 18 300–307.
Not in our library10.1038/mp.2012.198
174.
Krazeisen A. Breitling R. Imai K. Fritz S. Moller G. Adamski J. (1999 ). Determination of cDNA, gene structure and chromosomal localization of the novel human 17beta-hydroxysteroid dehydrogenase type 7(1). FEBS Lett. 460 373–379.
Not in our library10.1016/s0014-5793(99)01366-6
175.
Labrie F. Simard J. Luu-The V. Pelletier G. Bélanger A. Lachance Y. (1992 ). Structure and tissue-specific expression of 3ß-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues. J. Steroid Biochem. Mol. Biol. 41 421–435.
Not in our library10.1016/0960-0760(92)90368-s
176.
Lafond J. Charest M. C. Alain J. F. Brissette L. Masse A. Robidoux J. (1999 ). Presence of CLA-1 and HDL binding sites on syncytiotrophoblast brush border and basal plasma membranes of human placenta. Placenta 20 583–590.
Not in our library10.1053/plac.1999.0412
177.
Lamon-Fava S. (2013 ). Statins and lipid metabolism: an update. Curr. Opin. Lipidol. 24 221–226.
Not in our library10.1097/mol.0b013e3283613b8b
178.
Landers K. A. Li H. Mortimer R. H. McLeod D. S. A. d’Emden M. C. Richard K. (2018 ). Transthyretin uptake in placental cells is regulated by the high-density lipoprotein receptor, scavenger receptor class B member 1. Mol. Cell. Endocrinol.
Not in our library10.1016/j.mce.2018.02.014
179.
Landschulz K. T. Pathak R. K. Rigotti A. Krieger M. Hobbs H. H. (1996 ). Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J. Clin. Invest. 98 984–995.
Not in our library10.1172/jci118883
180.
Lang I. Hartmann M. Blaschitz A. Dohr G. Skofitsch G. Desoye G. (1993 ). Immunohistochemical evidence for the heterogeneity of maternal and fetal vascular endothelial cells in human full-term placenta. Cell Tissue Res. 274 211–218.
Not in our library10.1007/bf00318740
181.
Lang I. Pabst M. A. Hiden U. Blaschitz A. Dohr G. Hahn T. (2003 ). Heterogeneity of microvascular endothelial cells isolated from human term placenta and macrovascular umbilical vein endothelial cells. Eur. J. Cell Biol. 82 163–173.
Not in our library10.1078/0171-9335-00306
182.
Lang I. Schweizer A. Hiden U. Ghaffari-Tabrizi N. Hagendorfer G. Bilban M. (2008 ). Human fetal placental endothelial cells have a mature arterial and a juvenile venous phenotype with adipogenic and osteogenic differentiation potential. Differentiation 76 1031–1043.
Not in our library10.1111/j.1432-0436.2008.00302.x
183.
Larkin J. C. Sears S. B. Sadovsky Y. (2014 ). The influence of ligand-activated LXR on primary human trophoblasts. Placenta 35 919–924.
Not in our library10.1016/j.placenta.2014.09.002
184.
Lassance L. Haghiac M. Minium J. Catalano P. Hauguel-de Mouzon S. (2015 ). Obesity-induced down-regulation of the mitochondrial translocator protein (TSPO) impairs placental steroid production. J. Clin. Endocrinol. Metab. 100 E11–E18.
Not in our library10.1210/jc.2014-2792
185.
Lasuncion M. A. Bonet B. Knopp R. H. (1991 ). Mechanism of the HDL2 stimulation of progesterone secretion in cultured placental trophoblast. J. Lipid Res. 32 1073–1087.
Not in our library
186.
Leduc L. Delvin E. Ouellet A. Garofalo C. Grenier E. Morin L. (2011 ). Oxidized low-density lipoproteins in cord blood from neonates with intra-uterine growth restriction. Eur. J. Obstet. Gynecol. Reprod. Biol. 156 46–49.
Not in our library10.1016/j.ejogrb.2011.01.007
187.
Leeder J. S. Gaedigk R. Marcucci K. A. Gaedigk A. Vyhlidal C. A. Schindel B. P. (2005 ). Variability of CYP3A7 expression in human fetal liver. J. Pharmacol. Exp. Ther. 314 626–635.
Not in our library10.1124/jpet.105.086504
188.
Levitan I. Volkov S. Subbaiah P. V. (2010 ). Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid. Redox Signal. 13 39–75.
Not in our library10.1089/ars.2009.2733
189.
Levkovitz R. Zaretsky U. Gordon Z. Jaffa A. J. Elad D. (2013a ). In vitro simulation of placental transport: part I. Biological model of the placental barrier. Placenta 34 699–707.
Not in our library10.1016/j.placenta.2013.03.014
190.
Levkovitz R. Zaretsky U. Jaffa A.J. Hod M. Elad D. (2013b ). In vitro simulation of placental transport: part II. Glucose transfer across the placental barrier model. Placenta 34 708–715.
Not in our library10.1016/j.placenta.2013.05.006
191.
Li Y. Isomaa V. Pulkka A. Herva R. Peltoketo H. Vihko P. (2005 ). Expression of 3beta-hydroxysteroid dehydrogenase type 1, P450 aromatase, and 17beta-hydroxysteroid dehydrogenase types 1, 2, 5 and 7 mRNAs in human early and mid-gestation placentas. Placenta 26 387–392.
Not in our library10.1016/j.placenta.2004.07.008
192.
Lin D. S. Pitkin R. M. Connor W. E. (1977 ). Placental transfer of cholesterol into the human fetus. Am. J. Obstet. Gynecol. 128 735–739.
Not in our library10.1016/0002-9378(77)90713-x
193.
Lindegaard M. L. Olivecrona G. Christoffersen C. Kratky D. Hannibal J. Petersen B. L. (2005 ). Endothelial and lipoprotein lipases in human and mouse placenta. J. Lipid Res. 46 2339–2346.
Not in our library10.1194/jlr.m500277-jlr200
194.
Linton M. F. Tao H. Linton E. F. Yancey P. G. (2017 ). SR-BI: a multifunctional receptor in cholesterol homeostasis and atherosclerosis. Trends Endocrinol. Metab. 28 461–472.
Not in our library10.1016/j.tem.2017.02.001
195.
Liu L. Zhang M. Li L. Li C. Min X. Zheng M. (2014 ). Expression and clinical significance of ATP-binding cassette transporter 1 in serum and placental tissue in Chinese patients with preeclampsia. Gynecol. Obstet. Invest. 78 194–200.
Not in our library10.1159/000362551
196.
Liu S. Mao B. Bai Y. Liu J. Li H. Li X. (2016 ). Effects of methoxychlor and its metabolite hydroxychlor on human placental 3β-Hydroxysteroid dehydrogenase 1 and aromatase in JEG-3 cells. Pharmacology 97 126–133.
Not in our library10.1159/000442711
197.
Lou H. Le F. Zheng Y. Li L. Wang L. Wang N. (2014 ). Assisted reproductive technologies impair the expression and methylation of insulin-induced gene 1 and sterol regulatory element-binding factor 1 in the fetus and placenta. Fertil. Steril. 101 974.e2–980.e2.
Not in our library10.1016/j.fertnstert.2013.12.034
198.
Luo J. Jiang L. Yang H. Song B. L. (2017 ). Routes and mechanisms of post-endosomal cholesterol trafficking: a story that never ends. Traffic 18 209–217.
Not in our library10.1111/tra.12471
199.
Madsen E. M. Lindegaard M. L. Andersen C. B. Damm P. Nielsen L. B. (2004 ). Human placenta secretes apolipoprotein B-100-containing lipoproteins. J. Biol. Chem. 279 55271–55276.
Not in our library10.1074/jbc.m411404200
200.
Maezawa K. Matsunaga T. Takezawa T. Kanai M. Ohira S. Ohmori S. (2010 ). Cytochrome P450 3As gene expression and testosterone 6&beta-hydroxylase activity in human fetal membranes and placenta at full term. Biol. Pharm. Bull. 33 249–254.
Not in our library10.1248/bpb.33.249
201.
Majzoub J. A. Karalis K. P. (1999 ). Placental corticotropin-releasing hormone: function and regulation. Am. J. Obstet. Gynecol. 180(1 Pt 3), S242–S246.
Not in our library10.1016/s0002-9378(99)70708-8
202.
Makedou K. Kourtis A. Gkiomisi A. Toulis K. A. Mouzaki M. Anastasilakis A. D. (2011 ). Oxidized low-density lipoprotein and adiponectin levels in pregnancy. Gynecol. Endocrinol. 27 1070–1073.
Not in our library10.3109/09513590.2011.569793
203.
Malassine A. Frendo J. L. Evain-Brion D. (2003 ). A comparison of placental development and endocrine functions between the human and mouse model. Hum. Reprod. Update 9 531–539.
Not in our library10.1093/humupd/dmg043
204.
Maliqueo M. Lara H. E. Sánchez F. Echiburú B. Crisosto N. Sir-Petermann T. (2013 ). Placental steroidogenesis in pregnant women with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 166 151–155.
Not in our library10.1016/j.ejogrb.2012.10.015
205.
Manceau S. Giraud C. Declèves X. Scherrmann J. M. Artiguebieille F. Goffinet F. (2012 ). ABC drug transporter and nuclear receptor expression in human cytotrophoblasts: influence of spontaneous syncytialization and induction by glucocorticoids. Placenta 33 927–932.
Not in our library10.1016/j.placenta.2012.07.016
206.
Marceau G. Volle D. H. Gallot D. Mangelsdorf D. J. Sapin V. Lobaccaro J. M. (2005 ). Placental expression of the nuclear receptors for oxysterols LXRalpha and LXRbeta during mouse and human development. Anat. Rec. A Discov. Mol. Cell. Evol. Biol. 283 175–181.
Not in our library10.1002/ar.a.20157
207.
Mark P. J. Waddell B. J. (2006 ). P-glycoprotein restricts access of cortisol and dexamethasone to the glucocorticoid receptor in placental BeWo cells. Endocrinology 147 5147–5152.
Not in our library10.1210/en.2006-0633
208.
Marseille-Tremblay C. Ethier-Chiasson M. Forest J. C. Giguere Y. Masse A. Mounier C. (2008 ). Impact of maternal circulating cholesterol and gestational diabetes mellitus on lipid metabolism in human term placenta. Mol. Reprod. Dev. 75 1054–1062.
Not in our library10.1002/mrd.20842
209.
Marseille-Tremblay C. Gravel A. Lafond J. Mounier C. (2007 ). Effect of an enriched cholesterol diet during gestation on fatty acid synthase, HMG-CoA reductase and SREBP-1/2 expressions in rabbits. Life Sci. 81 772–778.
Not in our library10.1016/j.lfs.2007.07.016
210.
Maynard S. E. Min J.-Y. Merchan J. Lim K.-H. Li J. Mondal S. (2003 ). Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111 649–658.
Not in our library10.1172/jci200317189
211.
Mesiano S. (2001 ). Roles of Estrogen and Progesterone in Human Parturition, ed. Smith R. Basel: Karger, 86–104.
Not in our library10.1159/000061038
212.
Michael A. E. Papageorghiou A. T. (2008 ). Potential significance of physiological and pharmacological glucocorticoids in early pregnancy. Hum. Reprod. Update 14 497–517.
Not in our library10.1093/humupd/dmn021
213.
Miki Y. Nakata T. Suzuki T. Darnel A. D. Moriya T. Kaneko C. (2002 ). Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. J. Clin. Endocrinol. Metab. 87 5760–5768.
Not in our library10.1210/jc.2002-020670
214.
Miller W. L. (2013 ). Steroid hormone synthesis in mitochondria. Mol. Cell. Endocrinol. 379 62–73.
Not in our library10.1016/j.mce.2013.04.014
215.
Miller W. L. (2017 ). Steroidogenesis: unanswered questions. Trends Endocrinol. Metab. 28 771–793.
Not in our library10.1016/j.tem.2017.09.002
216.
Miller W. L. Auchus R. J. (2011 ). The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr. Rev. 32 81–151.
Not in our library10.1210/er.2010-0013
217.
Early steps in steroidogenesis: intracellular cholesterol trafficking · 2011
Not checked
218.
Maternal hormonal milieu influence on fetal brain development · 2018
No notice
219.
Increased maternal and fetal cholesterol efflux capacity and placental CYP27A1 expression in preeclampsia[S] · 2017
Not checked
220.
Moise J. Ilekis J. Scommegna A. Benveniste R. (1986 ). The effect of dehydroepiandrosterone sulfate on de novo and low-density lipoprotein-stimulated progesterone secretion by human choriocarcinoma JEG-3 cells. Am. J. Obstet. Gynecol. 154 1080–1085.
Not in our library10.1016/0002-9378(86)90755-6
221.
Moisiadis V. G. Matthews S. G. (2014a ). Glucocorticoids and fetal programming part 1: Outcomes. Nat. Rev. Endocrinol. 10 391–402.
Not in our library10.1038/nrendo.2014.73
222.
Moisiadis V. G. Matthews S. G. (2014b ). Glucocorticoids and fetal programming part 2: Mechanisms. Nat. Rev. Endocrinol. 10 403–411.
Not in our library10.1038/nrendo.2014.74
223.
Monreal-Flores J. Espinosa-Garcia M. T. Garcia-Regalado A. Arechavaleta-Velasco F. Martinez F. (2017 ). The heat shock protein 60 promotes progesterone synthesis in mitochondria of JEG-3 cells. Reprod. Biol. 17 154–161.
Not in our library10.1016/j.repbio.2017.04.001
224.
Montoudis A. Boileau S. Simoneau L. Lafond J. (2003 ). Impact of an enriched-cholesterol diet on enzymatic cholesterol metabolism during rabbit gestation. Life Sci. 73 1463–1477.
Not in our library10.1016/s0024-3205(03)00436-3
225.
Moon J.-Y. Moon M. H. Kim K. T. Jeong D. H. Kim Y. N. Chung B. C. (2014 ). Cytochrome P450-mediated metabolic alterations in preeclampsia evaluated by quantitative steroid signatures. J. Steroid Biochem. Mol. Biol. 139(Suppl. C), 182–191.
Not in our library10.1016/j.jsbmb.2013.02.014
226.
Murata M. Kodama H. Goto K. Hirano H. Tanaka T. (1996 ). Decreased very-low-density lipoprotein and low-density lipoprotein receptor messenger ribonucleic acid expression in placentas from preeclamptic pregnancies. Am. J. Obstet. Gynecol. 175 1551–1556.
Not in our library10.1016/s0002-9378(96)70105-9
227.
Mutemberezi V. Guillemot-Legris O. Muccioli G. G. (2016 ). Oxysterols: from cholesterol metabolites to key mediators. Prog. Lipid Res. 64 152–169.
Not in our library10.1016/j.plipres.2016.09.002
228.
Myllynen P. Vahakangas K. (2013 ). Placental transfer and metabolism: an overview of the experimental models utilizing human placental tissue. Toxicol. In Vitro 27 507–512.
Not in our library10.1016/j.tiv.2012.08.027
229.
Nakamura Y. Ikeda S. Furukawa T. Sumizawa T. Tani A. Akiyama S. (1997 ). Function of P-glycoprotein expressed in placenta and mole. Biochem. Biophys. Res. Commun. 235 849–853.
Not in our library10.1006/bbrc.1997.6855
230.
Naoum H. G. De Chazal R. C. Eaton B. M. Contractor S. F. (1987 ). Characterization and specificity of lipoprotein binding to term human placental membranes. Biochim. Biophys. Acta 902 193–199.
Not in our library10.1016/0005-2736(87)90295-1
231.
Napoli C. D’Armiento F. P. Mancini F. P. Postiglione A. Witztum J. L. Palumbo G. (1997 ). Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J. Clin. Invest. 100 2680–2690.
Not in our library10.1172/jci119813
232.
Napoli C. Glass C. K. Witztum J. L. Deutsch R. D’Armiento F. P. Palinski W. (1999 ). Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet 354 1234–1241.
Not in our library10.1016/s0140-6736(99)02131-5
233.
Nardozza L. M. Caetano A. C. Zamarian A. C. Mazzola J. B. Silva C. P. Marcal V. M. (2017 ). Fetal growth restriction: current knowledge. Arch. Gynecol. Obstet. 295 1061–1077.
Not in our library10.1007/s00404-017-4341-9
234.
Ni X. Hou Y. Yang R. Tang X. Smith R. Nicholson R. C. (2004 ). Progesterone receptors A and B differentially modulate corticotropin-releasing hormone gene expression through a cAMP regulatory element. Cell. Mol. Life Sci. 61 1114–1122.
Not in our library10.1007/s00018-004-4030-2
235.
Ni X. T. Duan T. Yang Z. Guo C. M. Li J. N. Sun K. (2009 ). Role of human chorionic gonadotropin in maintaining 11beta-hydroxysteroid dehydrogenase type 2 expression in human placental syncytiotrophoblasts. Placenta 30 1023–1028.
Not in our library10.1016/j.placenta.2009.10.005
236.
Ni Z. Mao Q. (2011 ). ATP-binding cassette efflux transporters in human placenta. Curr. Pharm. Biotechnol. 12 674–685.
Not in our library10.2174/138920111795164057
237.
Nikitina L. Wenger F. Baumann M. Surbek D. Korner M. Albrecht C. (2011 ). Expression and localization pattern of ABCA1 in diverse human placental primary cells and tissues. Placenta 32 420–430.
Not in our library10.1016/j.placenta.2011.03.003
238.
Noguchi S. Nishimura T. Fujibayashi A. Maruyama T. Tomi M. Nakashima E. (2015 ). Organic anion transporter 4-mediated transport of olmesartan at basal plasma membrane of human placental barrier. J. Pharm. Sci. 104 3128–3135.
Not in our library10.1002/jps.24434
239.
Noyola-Martinez N. Halhali A. Zaga-Clavellina V. Olmos-Ortiz A. Larrea F. Barrera D. (2017 ). A time-course regulatory and kinetic expression study of steroid metabolizing enzymes by calcitriol in primary cultured human placental cells. J. Steroid Biochem. Mol. Biol. 167 98–105.
Not in our library10.1016/j.jsbmb.2016.11.015
240.
Olvera-Sanchez S. Espinosa-Garcia M. T. Monreal J. Flores-Herrera O. Martinez F. (2011 ). Mitochondrial heat shock protein participates in placental steroidogenesis. Placenta 32 222–229.
Not in our library10.1016/j.placenta.2010.12.018
241.
Orendi K. Kivity V. Sammar M. Grimpel Y. Gonen R. Meiri H. (2011 ). Placental and trophoblastic in vitro models to study preventive and therapeutic agents for preeclampsia. Placenta 32 S49–S54.
Not in our library10.1016/j.placenta.2010.11.023
242.
Park M. C. Cayatte A. Subbiah M. T. (1988 ). Isolation and characterization of a novel lipoprotein particle from human placental extracts. Biochem. Biophys. Res. Commun. 153 502–509.
Not in our library10.1016/s0006-291x(88)81123-9
243.
Park M. N. Park K. H. Lee J. E. Shin Y. Y. An S. M. Kang S. S. (2018 ). The expression and activation of sex steroid receptors in the preeclamptic placenta. Int. J. Mol. Med. 41 2943–2951.
Not in our library10.3892/ijmm.2018.3474
244.
Parker C. R. Jr. Illingworth D. R. Bissonnette J. Carr B. R. (1986 ). Endocrine changes during pregnancy in a patient with homozygous familial hypobetalipoproteinemia. N. Engl. J. Med. 314 557–560.
Not in our library10.1056/nejm198602273140906
245.
Pasqualini J. R. Chetrite G. S. (2016 ). The formation and transformation of hormones in maternal, placental and fetal compartments: biological implications. Horm. Mol. Biol. Clin. Investig. 27 11–28.
Not in our library10.1515/hmbci-2016-0036
246.
Patel B. Elguero S. Thakore S. Dahoud W. Bedaiwy M. Mesiano S. (2015 ). Role of nuclear progesterone receptor isoforms in uterine pathophysiology. Hum. Reprod. Update 21 155–173.
Not in our library10.1093/humupd/dmu056
247.
Pavan L. Hermouet A. Tsatsaris V. Therond P. Sawamura T. Evain-Brion D. (2004 ). Lipids from oxidized low-density lipoprotein modulate human trophoblast invasion: involvement of nuclear liver X receptors. Endocrinology 145 4583–4591.
Not in our library10.1210/en.2003-1747
248.
Pavek P. Smutny T. (2014 ). Nuclear receptors in regulation of biotransformation enzymes and drug transporters in the placental barrier. Drug Metab. Rev. 46 19–32.
Not in our library10.3109/03602532.2013.835819
249.
Payne A. H. Hales D. B. (2004 ). Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr. Rev. 25 947–970.
Not in our library10.1210/er.2003-0030
250.
Pepe G. J. Albrecht E. D. (1995 ). Actions of placental and fetal adrenal steroid hormones in primate pregnancy. Endocr. Rev. 16 608–648.
Not in our library10.1210/edrv-16-5-608
251.
Perez-Sepulveda A. Monteiro L. J. Dobierzewska A. España-Perrot P. P. Venegas-Araneda P. Guzmán-Rojas A. M. (2015 ). Placental aromatase is deficient in placental ischemia and preeclampsia. PLoS One 10:e0139682.
Not in our library10.1371/journal.pone.0139682
252.
Pezzi V. Mathis J. M. Rainey W. E. Carr B. R. (2003 ). Profiling transcript levels for steroidogenic enzymes in fetal tissues. J. Steroid Biochem. Mol. Biol. 87 181–189.
Not in our library10.1016/j.jsbmb.2003.07.006
253.
Molecular Mechanisms of Cellular Cholesterol Efflux · 2014
No notice
254.
Phillips R. J. Fortier M. A. Lopez Bernal A. (2014 ). Prostaglandin pathway gene expression in human placenta, amnion and choriodecidua is differentially affected by preterm and term labour and by uterine inflammation. BMC Pregnancy Childbirth 14:241.
Not in our library10.1186/1471-2393-14-241
255.
Piltonen T. T. Chen J. C. Khatun M. Kangasniemi M. Liakka A. Spitzer T. (2015 ). Endometrial stromal fibroblasts from women with polycystic ovary syndrome have impaired progesterone-mediated decidualization, aberrant cytokine profiles and promote enhanced immune cell migration in vitro. Hum. Reprod. 30 1203–1215.
Not in our library10.1093/humrep/dev055
256.
Pitkin R. M. Connor W. E. Lin D. S. (1972 ). Cholesterol metabolism and placental transfer in the pregnant Rhesus monkey. J. Clin. Invest. 51 2584–2592.
Not in our library10.1172/jci107075
257.
Plosch T. Gellhaus A. van Straten E. M. Wolf N. Huijkman N. C. Schmidt M. (2010 ). The liver X receptor (LXR) and its target gene ABCA1 are regulated upon low oxygen in human trophoblast cells: a reason for alterations in preeclampsia? Placenta 31 910–918.
Not in our library10.1016/j.placenta.2010.07.009
258.
Plosch T. van Straten E. M. Kuipers F. (2007 ). Cholesterol transport by the placenta: placental liver X receptor activity as a modulator of fetal cholesterol metabolism? Placenta 28 604–610.
Not in our library10.1016/j.placenta.2006.10.009
259.
Plotz E. J. Kabara J. J. Davis M. E. LeRoy G. V. Gould R. G. (1968 ). Studies on the synthesis of cholesterol in the brain of the human fetus. Am. J. Obstet. Gynecol. 101 534–538.
Not in our library10.1016/0002-9378(68)90565-6
260.
Pluchino N. Russo M. Genazzani A. R. (2016 ). The fetal brain: role of progesterone and allopregnanolone. Horm Mol. Biol. Clin. Investig. 27 29X–34X.
Not in our library10.1515/hmbci-2016-0020
261.
Pratt J. P. Kaucher M. Moyer E. Richards A. J. Williams H. H. (1946 ). Composition of the human placenta; lipid content. Am. J. Obstet. Gynecol. 52 665–668.
Not in our library10.1016/0002-9378(46)90135-4
262.
Prouillac C. Lecoeur S. (2010 ). The role of the placenta in fetal exposure to xenobiotics: importance of membrane transporters and human models for transfer studies. Drug Metab. Dispos. 38 1623–1635.
Not in our library10.1124/dmd.110.033571
263.
Qiu C. Phung T. T. Vadachkoria S. Muy-Rivera M. Sanchez S. E. Williams M. A. (2006 ). Oxidized low-density lipoprotein (Oxidized LDL) and the risk of preeclampsia. Physiol. Res. 55 491–500.
Not in our library10.33549/physiolres.930813
264.
Rani P. R. Begum J. (2016 ). Screening and diagnosis of gestational diabetes mellitus, where do we stand. J. Clin. Diagn. Res. 10 QE01–QE04.
Not in our library10.7860/jcdr/2016/17588.7689
265.
Rantakari P. Strauss L. Kiviranta R. Lagerbohm H. Paviala J. Holopainen I. (2008 ). Placenta defects and embryonic lethality resulting from disruption of mouse hydroxysteroid (17-β) dehydrogenase 2 gene. Mol. Endocrinol. 22 665–675.
Not in our library10.1210/me.2007-0257
266.
Rebourcet R. Alsat E. Mondon F. Berthelier M. Pastier D. Cedard L. (1986 ). Detection of distinct receptors for native and acetylated low-density lipoproteins in human placental microvilli by ligand-immunoblotting. Biochimie 68 1135–1140.
Not in our library10.1016/s0300-9084(86)80189-4
267.
Reyes L. Wolfe B. Golos T. (2017 ). Hofbauer cells: placental macrophages of fetal origin. Results Probl. Cell Differ. 62 45–60.
Not in our library10.1007/978-3-319-54090-0_3
268.
Riley S. C. Walton J. C. Herlick J. M. Challis J. R. (1991 ). The localization and distribution of corticotropin-releasing hormone in the human placenta and fetal membranes throughout gestation. J. Clin. Endocrinol. Metab. 72 1001–1007.
Not in our library10.1210/jcem-72-5-1001
269.
Rindler M. J. Traber M. G. Esterman A. L. Bersinger N. A. Dancis J. (1991 ). Synthesis and secretion of apolipoprotein E by human placenta and choriocarcinoma cell lines. Placenta 12 615–624.
Not in our library10.1016/0143-4004(91)90496-3
270.
Robinson B. G. Emanuel R. L. Frim D. M. Majzoub J. A. (1988 ). Glucocorticoid stimulates expression of corticotropin-releasing hormone gene in human placenta. Proc. Natl. Acad. Sci. U.S.A. 85 5244–5248.
Not in our library10.1073/pnas.85.14.5244
271.
Rohrl C. Stangl H. (2013 ). HDL endocytosis and resecretion. Biochim. Biophys. Acta 1831 1626–1633.
Not in our library10.1016/j.bbalip.2013.07.014
272.
Romano A. Delvoux B. Fischer D.-C. Groothuis P. (2007 ). The PROGINS polymorphism of the human progesterone receptor diminishes the response to progesterone. J. Mol. Endocrinol. 38 331–350.
Not in our library10.1677/jme.1.02170
273.
Sacks F. M. (2015 ). The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr. Opin. Lipidol. 26 56–63.
Not in our library10.1097/mol.0000000000000146
274.
Sati L. Seval Y. Yasemin Demir A. Kosanke G. Kohnen G. Demir R. (2007 ). Cellular diversity of human placental stem villi: an ultrastructural and immunohistochemical study. Acta Histochem. 109 468–479.
Not in our library10.1016/j.acthis.2007.04.006
275.
Sattar N. Greer I. A. Galloway P. J. Packard C. J. Shepherd J. Kelly T. (1999 ). Lipid and lipoprotein concentrations in pregnancies complicated by intrauterine growth restriction. J. Clin. Endocrinol. Metab. 84 128–130.
Not in our library10.1210/jcem.84.1.5419
276.
Transport of cholesterol across a BeWo cell monolayer · 2003
Not checked
277.
Schock H. Surcel H. M. Zeleniuch-Jacquotte A. Grankvist K. Lakso H. A. Fortner R. T. (2014 ). Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer. Endocr. Relat. Cancer 21 831–844.
Not in our library10.1530/erc-14-0282
278.
Schroepfer G. J. Jr. (2000 ). Oxysterols: modulators of cholesterol metabolism and other processes. Physiol. Rev. 80 361–554.
Not in our library10.1152/physrev.2000.80.1.361
279.
Schweigmann H. Sánchez-Guijo A. Ugele B. Hartmann K. Hartmann M. F. Bergmann M. (2014 ). Transport of the placental estriol precursor 16α-hydroxy-dehydroepiandrosterone sulfate (16α-OH-DHEAS) by stably transfected OAT4-, SOAT-, and NTCP-HEK293 cells. J. Steroid Biochem. Mol. Biol. 143(Suppl. C), 259–265.
Not in our library10.1016/j.jsbmb.2014.03.013
280.
Sfakianaki A. K. Norwitz E. R. (2006 ). Mechanisms of progesterone action in inhibiting prematurity. J. Matern. Fetal Neonatal Med. 19 763–772.
Not in our library10.1080/14767050600949829
281.
Shao X. Liu Y. Liu M. Wang Y. Yan L. Wang H. (2017 ). Testosterone represses estrogen signaling by upregulating miR-22: a mechanism for imbalanced steroid hormone production in preeclampsia. Hypertension 69 721–730.
Not in our library10.1161/hypertensionaha.116.08468
282.
Sharifzadeh F. Kashanian M. Fatemi F. (2012 ). A comparison of serum androgens in pre-eclamptic and normotensive pregnant women during the third trimester of pregnancy. Gynecol. Endocrinol. 28 834–836.
Not in our library10.3109/09513590.2012.683061
283.
Shi W. Swan K. F. Lear S. R. O’Neil J. S. Erickson S. K. Henson M. C. (1999 ). Regulation of pathways determining cholesterol availability in the baboon placenta with advancing gestation. Biol. Reprod. 61 1499–1505.
Not in our library10.1095/biolreprod61.6.1499
284.
Shimano H. Sato R. (2017 ). SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. Nat. Rev. Endocrinol. 13 710–730.
Not in our library10.1038/nrendo.2017.91
285.
Shin Y. Y. Jeong J. S. Park M. N. Lee J. E. An S. M. Cho W. S. (2018 ). Regulation of steroid hormones in the placenta and serum of women with preeclampsia. Mol. Med. Rep. 17 2681–2688.
Not in our library10.3892/mmr.2017.8165
286.
Siiteri P. K. MacDonald P. C. (1966 ). Placental estrogen biosynthesis during human pregnancy. J. Clin. Endocrinol. Metab. 26 751–761.
Not in our library10.1210/jcem-26-7-751
287.
Simpson E. R. Porter J. C. Milewich L. Bilheimer D. W. MacDonald P. C. (1978 ). Regulation by plasma lipoproteins of progesterone biosynthesis and 3-hydroxy-3-methyl glutaryl coenzyme a reductase activity in cultured human choriocarcinoma cells. J. Clin. Endocrinol. Metab. 47 1099–1105.
Not in our library10.1210/jcem-47-5-1099
288.
Slominski A. Semak I. Wortsman J. Zjawiony J. Li W. Zbytek B. (2006 ). An alternative pathway of vitamin D(2) metabolism cytochrome P450scc (CYP11A1)-mediated conversion to 20-hydroxyvitamin D(2) and 17,20-dihydroxyvitamin D(2). FEBS J. 273 2891–2901.
Not in our library10.1111/j.1742-4658.2006.05302.x
289.
Slominski A. Semak I. Zjawiony J. Wortsman J. Li W. Szczesniewski A. (2005 ). The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism. FEBS J. 272 4080–4090.
Not in our library10.1111/j.1742-4658.2005.04819.x
290.
Slominski A. T. Kim T.-K. Chen J. Nguyen M. N. Li W. Yates C. R. (2012 ). Cytochrome P450scc-dependent metabolism of 7-dehydrocholesterol in placenta and epidermal keratinocytes. Int. J. Biochem. Cell Biol. 44 2003–2018.
Not in our library10.1016/j.biocel.2012.07.027
291.
Detection of novel CYP11A1-derived secosteroids in the human epidermis and serum and pig adrenal gland · 2015
No notice
292.
Slominski A. T. Li W. Kim T.-K. Semak I. Wang J. Zjawiony J. K. (2015b ). Novel activities of CYP11A1 and their potential physiological significance. J. Steroid Biochem. Mol. Biol. 151 25–37.
Not in our library10.1016/j.jsbmb.2014.11.010
293.
Slominski A. T. Zmijewski M. A. Semak I. Sweatman T. Janjetovic Z. Li W. (2009 ). Sequential metabolism of 7-dehydrocholesterol to steroidal 5,7-dienes in adrenal glands and its biological implication in the skin. PLoS One 4:e4309.
Not in our library10.1371/journal.pone.0004309
294.
Slominski A. T. Zmijewski M. A. Zbytek B. Tobin D. J. Theoharides T. C. Rivier J. (2013 ). Key role of CRF in the skin stress response system. Endocr. Rev. 34 827–884.
Not in our library10.1210/er.2012-1092
295.
Snipes G. J. Suter U. (1997 ). Cholesterol and myelin. Subcell. Biochem. 28 173–204.
Not in our library10.1007/978-1-4615-5901-6_7
296.
Soffientini U. Graham A. (2016 ). Intracellular cholesterol transport proteins: roles in health and disease. Clin. Sci. 130 1843–1859.
Not in our library10.1042/cs20160339
297.
Stanley E. L. Hume R. Visser T. J. Coughtrie M. W. (2001 ). Differential expression of sulfotransferase enzymes involved in thyroid hormone metabolism during human placental development. J. Clin. Endocrinol. Metab. 86 5944–5955.
Not in our library10.1210/jcem.86.12.8081
298.
Stefulj J. Panzenboeck U. Becker T. Hirschmugl B. Schweinzer C. Lang I. (2009 ). Human endothelial cells of the placental barrier efficiently deliver cholesterol to the fetal circulation via ABCA1 and ABCG1. Circ. Res. 104 600–608.
Not in our library10.1161/circresaha.108.185066
299.
Steinberg M. L. Robins J. C. (2016 ). Cellular models of trophoblast differentiation. Semin. Reprod. Med. 34 50–56.
Not in our library10.1055/s-0035-1570026
300.
Stirrat L. I. Sengers B. G. Norman J. E. Homer N. Z. M. Andrew R. Lewis R. M. (2018 ). transfer and metabolism of cortisol by the isolated perfused human placenta. J. Clin. Endocrinol. Metab. 103 640–648.
Not in our library10.1210/jc.2017-02140
301.
St-Pierre M. V. Hagenbuch B. Ugele B. Meier P. J. Stallmach T. (2002 ). Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta. J. Clin. Endocrinol. Metab. 87 1856–1863.
Not in our library10.1210/jcem.87.4.8431
302.
Sugawara T. Holt J. A. Driscoll D. Strauss J. F. Lin D. Miller W. L. (1995 ). Human steroidogenic acute regulatory protein: functional activity in COS-1 cells, tissue-specific expression, and mapping of the structural gene to 8p11.2 and a pseudogene to chromosome 13. Proc. Natl. Acad. Sci. U.S.A. 92 4778–4782.
Not in our library10.1073/pnas.92.11.4778
303.
Sun K. Adamson S. L. Yang K. Challis J. R. (1999 ). Interconversion of cortisol and cortisone by 11beta-hydroxysteroid dehydrogenases type 1 and 2 in the perfused human placenta. Placenta 20 13–19.
Not in our library10.1053/plac.1998.0352
304.
Sun Y. Kopp S. Strutz J. Gali C. C. Zandl-Lang M. Fanaee-Danesh E. (2018 ). Gestational diabetes mellitus modulates cholesterol homeostasis in human fetoplacental endothelium. Biochim. Biophys. Acta 1863 968–979.
Not in our library10.1016/j.bbalip.2018.05.005
305.
Suzuki T. Miki Y. Nakata T. Shiotsu Y. Akinaga S. Inoue K. (2003 ). Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma. J. Steroid Biochem. Mol. Biol. 86 449–454.
Not in our library10.1016/s0960-0760(03)00356-x
306.
Takeyama J. Sasano H. Suzuki T. Iinuma K. Nagura H. Andersson S. (1998 ). 17Beta-hydroxysteroid dehydrogenase types 1 and 2 in human placenta: an immunohistochemical study with correlation to placental development. J. Clin. Endocrinol. Metab. 83 3710–3715.
Not in our library10.1210/jcem.83.10.5212
307.
Tartakover-Matalon S. Cherepnin N. Kuchuk M. Drucker L. Kenis I. Fishman A. (2007 ). Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression. Hum. Reprod. 22 1161–1167.
Not in our library10.1093/humrep/del464
308.
Telegdy G. Weeks J. W. Lerner U. Stakemann G. Diczfalusy E. (1970 ). Acetate and cholesterol metabolism in the human foeto-placental unit at midgestation. 1. Sunthesis of cholesterol. Acta Endocrinol. 63 91–104.
Not in our library10.1530/acta.0.0630091
309.
Thibeault A. H. Sanderson J. T. Vaillancourt C. (2018 ). Co-culture of H295R adrenocortical carcinoma and bewo choriocarcinoma cells to study feto-placental interactions: focus on estrogen biosynthesis. Methods Mol. Biol. 1710 295–304.
Not in our library10.1007/978-1-4939-7498-6_23
310.
The structural biology of oestrogen metabolism · 2013
No notice
311.
Thomson M. (2013 ). The physiological roles of placental corticotropin releasing hormone in pregnancy and childbirth. J. Physiol. Biochem. 69 559–573.
Not in our library10.1007/s13105-012-0227-2
312.
Tint G. S. Salen G. Batta A. K. Shefer S. Irons M. Elias E. R. (1995 ). Correlation of severity and outcome with plasma sterol levels in variants of the Smith-Lemli-Opitz syndrome. J. Pediatr. 127 82–87.
Not in our library10.1016/s0022-3476(95)70261-x
313.
Tiwari D. Bose P. D. Sultana R. Das C. R. Bose S. (2016 ). Preterm delivery and associated negative pregnancy outcome – A tale of faulty progesterone receptor signalling pathway and linked derailed immunomodulation: a study from Northeast India. J. Reprod. Immunol. 118(Suppl. C), 76–84.
Not in our library10.1016/j.jri.2016.10.001
314.
Tomi M. Eguchi H. Ozaki M. Tawara T. Nishimura S. Higuchi K. (2015 ). Role of OAT4 in uptake of estriol precursor 16α-hydroxydehydroepiandrosterone sulfate into human placental syncytiotrophoblasts from fetus. Endocrinology 156 2704–2712.
Not in our library10.1210/en.2015-1130
315.
Tomi M. Miyata Y. Noguchi S. Nishimura S. Nishimura T. Nakashima E. (2014 ). Role of protein kinase A in regulating steroid sulfate uptake for estrogen production in human placental choriocarcinoma cells. Placenta 35 658–660.
Not in our library10.1016/j.placenta.2014.06.003
316.
Tranquilli A. L. Dekker G. Magee L. Roberts J. Sibai B. M. Steyn W. (2014 ). The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 4 97–104.
Not in our library10.1016/j.preghy.2014.02.001
317.
Trapani L. Pallottini V. (2010 ). Age-related hypercholesterolemia and HMG-CoA reductase dysregulation: sex does matter (a gender perspective). Curr. Gerontol. Geriatr. Res. 2010:420139.
Not in our library10.1155/2010/420139
318.
Trapani L. Violo F. Pallottini V. (2010 ). Hypercholesterolemia and 3-hydroxy-3-methylglutaryl coenzyme A reductase regulation in aged female rats. Exp. Gerontol. 45 119–128.
Not in our library10.1016/j.exger.2009.10.014
319.
Tuckey R. C. (2005 ). Progesterone synthesis by the human placenta. Placenta 26 273–281.
Not in our library10.1016/j.placenta.2004.06.012
320.
Tuckey R. C. Bose H. S. Czerwionka I. Miller W. L. (2004 ). Molten globule structure and steroidogenic activity of N-218 MLN64 in human placental mitochondria. Endocrinology 145 1700–1707.
Not in our library10.1210/en.2003-1034
321.
Ugele B. Bahn A. Rex-Haffner M. (2008 ). Functional differences in steroid sulfate uptake of organic anion transporter 4 (OAT4) and organic anion transporting polypeptide 2B1 (OATP2B1) in human placenta. J. Steroid Biochem. Mol. Biol. 111 1–6.
Not in our library10.1016/j.jsbmb.2008.04.001
322.
Ugele B. St-Pierre M. V. Pihusch M. Bahn A. Hantschmann P. (2003 ). Characterization and identification of steroid sulfate transporters of human placenta. Am. J. Physiol. Endocrinol. Metab. 284 E390–E398.
Not in our library10.1152/ajpendo.00257.2002
323.
Uhr M. Holsboer F. Muller M. B. (2002 ). Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J. Neuroendocrinol. 14 753–759.
Not in our library10.1046/j.1365-2826.2002.00836.x
324.
Ulrich V. Gelber S. E. Vukelic M. Sacharidou A. Herz J. Urbanus R. T. (2016 ). ApoE receptor 2 mediation of trophoblast dysfunction and pregnancy complications induced by antiphospholipid antibodies in mice. Arthritis Rheumatol. 68 730–739.
Not in our library10.1002/art.39453
325.
Uzun H. Benian A. Madazli R. Topcuoglu M. A. Aydin S. Albayrak M. (2005 ). Circulating oxidized low-density lipoprotein and paraoxonase activity in preeclampsia. Gynecol. Obstet. Invest. 60 195–200.
Not in our library10.1159/000087205
326.
Valbuena-Diez A. C. Blanco F. J. Oujo B. Langa C. Gonzalez-Nunez M. Llano E. (2012 ). Oxysterol-induced soluble endoglin release and its involvement in hypertension. Circulation 126 2612–2624.
Not in our library10.1161/circulationaha.112.101261
327.
van Beek J. P. Guan H. Julan L. Yang K. (2004 ). Glucocorticoids stimulate the expression of 11beta-hydroxysteroid dehydrogenase type 2 in cultured human placental trophoblast cells. J. Clin. Endocrinol. Metab. 89 5614–5621.
Not in our library10.1210/jc.2004-0113
328.
Vejux A. Malvitte L. Lizard G. (2008 ). Side effects of oxysterols: cytotoxicity, oxidation, inflammation, and phospholipidosis. Braz. J. Med. Biol. Res. 41 545–556.
Not in our library10.1590/s0100-879x2008000700001
329.
Voutilainen R. Miller W. L. (1986 ). Developmental expression of genes for the stereoidogenic enzymes P450scc (20,22-desmolase), P450c17 (17 alpha-hydroxylase/17,20-lyase), and P450c21 (21-hydroxylase) in the human fetus. J. Clin. Endocrinol. Metab. 63 1145–1150.
Not in our library10.1210/jcem-63-5-1145
330.
Wadsack C. Desoye G. Hiden U. (2012 ). The feto-placental endothelium in pregnancy pathologies. Wien. Med. Wochenschr. 162 220–224.
Not in our library10.1007/s10354-012-0075-2
331.
Wadsack C. Hammer A. Levak-Frank S. Desoye G. Kozarsky K. F. Hirschmugl B. (2003 ). Selective cholesteryl ester uptake from high density lipoprotein by human first trimester and term villous trophoblast cells. Placenta 24 131–143.
Not in our library10.1053/plac.2002.0912
332.
Wadsack C. Tabano S. Maier A. Hiden U. Alvino G. Cozzi V. (2007 ). Intrauterine growth restriction is associated with alterations in placental lipoprotein receptors and maternal lipoprotein composition. Am. J. Physiol. Endocrinol. Metab. 292 E476–E484.
Not in our library10.1152/ajpendo.00547.2005
333.
Walker N. Filis P. Soffientini U. Bellingham M. O’Shaughnessy P. J. Fowler P. A. (2017 ). Placental transporter localization and expression in the human: the importance of species, sex, and gestational age differencesdagger. Biol. Reprod. 96 733–742.
Not in our library10.1093/biolre/iox012
334.
Walsh M. T. Hussain M. M. (2017 ). Targeting microsomal triglyceride transfer protein and lipoprotein assembly to treat homozygous familial hypercholesterolemia. Crit. Rev. Clin. Lab. Sci. 54 26–48.
Not in our library10.1080/10408363.2016.1221883
335.
Wan J. Hu Z. Zeng K. Yin Y. Zhao M. Chen M. (2018 ). The reduction in circulating levels of estrogen and progesterone in women with preeclampsia. Pregnancy Hypertens. 11 18–25.
Not in our library10.1016/j.preghy.2017.12.003
336.
Wang C. Yang J. Hao Z. Gong C. Tang L. Xu Y. (2017 ). Suppression of progesterone synthesis in human trophoblast cells by fine particulate matter primarily derived from industry. Environ. Pollut. 231(Pt 1), 1172–1180.
Not in our library10.1016/j.envpol.2017.08.029
337.
Wang W. Li J. Ge Y. Li W. Shu Q. Guan H. (2012 ). Cortisol induces aromatase expression in human placental syncytiotrophoblasts through the cAMP/Sp1 pathway. Endocrinology 153 2012–2022.
Not in our library10.1210/en.2011-1626
338.
Wang W. S. Liu C. Li W. J. Zhu P. Li J. N. Sun K. (2014 ). Involvement of CRH and hCG in the induction of aromatase by cortisol in human placental syncytiotrophoblasts. Placenta 35 30–36.
Not in our library10.1016/j.placenta.2013.10.018
339.
Warren W. B. Silverman A. J. (1995 ). Cellular localization of corticotrophin releasing hormone in the human placenta, fetal membranes and decidua. Placenta 16 147–156.
Not in our library10.1016/0143-4004(95)90003-9
340.
Weedon-Fekjaer M. S. Dalen K. T. Solaas K. Staff A. C. Duttaroy A. K. Nebb H. I. (2010a ). Activation of LXR increases acyl-CoA synthetase activity through direct regulation of ACSL3 in human placental trophoblast cells. J. Lipid Res. 51 1886–1896.
Not in our library10.1194/jlr.m004978
341.
Weedon-Fekjaer M. S. Johnsen G. M. Anthonisen E. H. Sugulle M. Nebb H. I. Duttaroy A. K. (2010b ). Expression of liver X receptors in pregnancies complicated by preeclampsia. Placenta 31 818–824.
Not in our library10.1016/j.placenta.2010.06.015
342.
Weissgerber T. L. Wolfe L. A. (2006 ). Physiological adaptation in early human pregnancy: adaptation to balance maternal-fetal demands. Appl. Physiol. Nutr. Metab. 31 1–11.
Not in our library10.1139/h05-003
343.
Wetendorf M. DeMayo F. J. (2012 ). The progesterone receptor regulates implantation, decidualization, and glandular development via a complex paracrine signaling network. Mol. Cell. Endocrinol. 357 108–118.
Not in our library10.1016/j.mce.2011.10.028
344.
Wetendorf M. DeMayo F. J. (2014 ). Progesterone receptor signaling in the initiation of pregnancy and preservation of a healthy uterus. Int. J. Dev. Biol. 58 95–106.
Not in our library10.1387/ijdb.140069mw
345.
Whirledge S. DeFranco D. B. (2018 ). Glucocorticoid signaling in health and disease: insights from tissue-specific GR knockout mice. Endocrinology 159 46–64.
Not in our library10.1210/en.2017-00728
346.
Winkel C. A. Gilmore J. MacDonald P. C. Simpson E. R. (1980a ). Uptake and degradation of lipoproteins by human trophoblastic cells in primary culture. Endocrinology 107 1892–1898.
Not in our library10.1210/endo-107-6-1892
347.
Winkel C. A. Snyder J. M. Macdonald P. C. Simpson E. R. (1980b ). Regulation of cholesterol and progesterone synthesis in human placental cells in culture by serum lipoproteins. Endocrinology 106 1054–1060.
Not in our library10.1210/endo-106-4-1054
348.
Winkel C. A. MacDonald P. C. Simpson E. R. (1981 ). The role of receptor-mediated low-density lipoprotein uptake and degradation in the regulation of progesterone biosynthesis and cholesterol metabolism by human trophoblasts. Placenta Suppl. 3 133–143.
Not in our library
349.
Maternal 27-hydroxycholesterol concentrations during the course of pregnancy and in pregnancy pathologies · 2017
Not checked
350.
Winkler K. Wetzka B. Hoffmann M. M. Friedrich I. Kinner M. Baumstark M. W. (2000 ). Low density lipoprotein (LDL) subfractions during pregnancy: accumulation of buoyant LDL with advancing gestation. J. Clin. Endocrinol. Metab. 85 4543–4550.
Not in our library10.1210/jcem.85.12.7027
351.
Wittmaack F. M. Gafvels M. E. Bronner M. Matsuo H. Mccrae K. R. Tomaszewski J. E. (1995 ). Localization and regulation of the human very-low-density lipoprotein apolipoprotein-e receptor - trophoblast expression predicts a role for the receptor in placental lipid transport. Endocrinology 136 340–348.
Not in our library10.1210/en.136.1.340
352.
Woo C. S. J. Wan M. L. Y. Ahokas J. El-Nezami H. (2013 ). Potential endocrine disrupting effect of ochratoxin A on human placental 3β-hydroxysteroid dehydrogenase/isomerase in JEG-3 cells at levels relevant to human exposure. Reprod. Toxicol. 38 47–52.
Not in our library10.1016/j.reprotox.2013.02.034
353.
Woollett L. Heubi J. E. (2000 ). “Fetal and neonatal cholesterol metabolism,” in Endotext, eds De Groot L. J. Chrousos G. Dungan K. Feingold K. R. Grossman A. Hershman J. M. Koch C. Korbonits M. McLachlan R. New M. Purnell J. Rebar R. Singer F. Vinik A. (South Dartmouth MA: MDText.com Inc.).
Not in our library
354.
Woollett L. A. (1996 ). Origin of cholesterol in the fetal golden Syrian hamster: contribution of de novo sterol synthesis and maternal-derived lipoprotein cholesterol. J. Lipid Res. 37 1246–1257.
Not in our library
355.
Woollett L. A. (2005 ). Maternal cholesterol in fetal development: transport of cholesterol from the maternal to the fetal circulation. Am. J. Clin. Nutr. 82 1155–1161.
Not in our library10.1093/ajcn/82.6.1155
356.
Woollett L. A. (2011 ). Review: transport of maternal cholesterol to the fetal circulation. Placenta 32(Suppl. 2), S218–S221.
Not in our library10.1016/j.placenta.2011.01.011
357.
Wu L. Yan J. Qu S. C. Feng Y. Q. Jiang X. L. (2012 ). Abnormal regulation for progesterone production in placenta with prenatal cocaine exposure in rats. Placenta 33 977–981.
Not in our library10.1016/j.placenta.2012.10.001
358.
Yang H. Y. Lee Q. P. Rettie A. E. Juchau M. R. (1994 ). Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Mol. Pharmacol. 46 922–928.
Not in our library
359.
Yang Q. Wang W. Liu C. Wang Y. Sun K. (2016 ). Compartmentalized localization of 11beta-HSD 1 and 2 at the feto-maternal interface in the first trimester of human pregnancy. Placenta 46 63–71.
Not in our library10.1016/j.placenta.2016.08.079
360.
Yang R. You X. Tang X. Gao L. Ni X. (2006 ). Corticotropin-releasing hormone inhibits progesterone production in cultured human placental trophoblasts. J. Mol. Endocrinol. 37 533–540.
Not in our library10.1677/jme.1.02119
361.
Yao L. Jenkins K. Horn P. S. Lichtenberg M. H. Woollett L. A. (2007 ). Inability to fully suppress sterol synthesis rates with exogenous sterol in embryonic and extraembyronic fetal tissues. Biochim. Biophys. Acta 1771 1372–1379.
Not in our library10.1016/j.bbalip.2007.09.002
362.
Yoshida N. Osawa Y. (1991 ). Purification of human placental aromatase cytochrome P-450 with monoclonal antibody and its characterization. Biochemistry 30 3003–3010.
Not in our library10.1021/bi00226a004
363.
You X. Yang R. Tang X. Gao L. Ni X. (2006 ). Corticotropin-releasing hormone stimulates estrogen biosynthesis in cultured human placental trophoblasts. Biol. Reprod. 74 1067–1072.
Not in our library10.1095/biolreprod.105.049361
364.
Zabul P. Wozniak M. Slominski A. T. Preis K. Gorska M. Korozan M. (2015 ). A Proposed molecular mechanism of high-dose vitamin D3 supplementation in prevention and treatment of preeclampsia. Int. J. Mol. Sci. 16 13043–13064.
Not in our library10.3390/ijms160613043
365.
Zarrouk A. Vejux A. Mackrill J. O’Callaghan Y. Hammami M. O’Brien N. (2014 ). Involvement of oxysterols in age-related diseases and ageing processes. Ageing Res. Rev. 18 148–162.
Not in our library10.1016/j.arr.2014.09.006
366.
Zeybek B. Costantine M. Kilic G. S. Borahay M. A. (2018 ). Therapeutic roles of statins in gynecology and obstetrics: the current evidence. Reprod. Sci. 25 802–817.
Not in our library10.1177/1933719117750751
367.
Zhang E. G. Burton G. J. Smith S. K. Charnock-Jones D. S. (2002 ). Placental vessel adaptation during gestation and to high altitude: changes in diameter and perivascular cell coverage. Placenta 23 751–762.
Not in our library10.1053/plac.2002.0856
368.
Modulation of cholesterol transport by maternal hypercholesterolemia in human full-term placenta. · 2017
Not checked
369.
Zhao C. Dahlman-Wright K. (2010 ). Liver X receptor in cholesterol metabolism. J. Endocrinol. 204 233–240.
Not in our library10.1677/joe-09-0271
370.
Zhu X. M. Han T. Sargent I. L. Yin G. W. Yao Y. Q. (2009 ). Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnancies. Am. J. Obstet. Gynecol. 200 661.e1–667.e1.
Not in our library10.1016/j.ajog.2008.12.045

Cited by papers we hold 3

Biomarkers for central serous chorioretinopathy · 2020
Not checked
The Role of Arachidonic and Linoleic Acid Derivatives in Pathological Pregnancies and the Human Reproduction Process · 2020
No notice
Aspectos generales del transporte de colesterol en la esteroidogénesis de la placenta humana · 2019
Not checked

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.